[
    {
        "content": "* Merck & Co reports 6.5 percent passive stake in Spero Therapeutics Inc as of Nov 6 - SEC Filing\u200b Source text: [http://bit.ly/2z57b4q] Further company coverage:",
        "date": "11152017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck reports 6.5 pct passive stake in Spero Therapeutics as of Nov 6 "
    },
    {
        "content": "* \u200dCue Biopharma says a strategic research collaboration and license agreement with Merck",
        "date": "11162017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Cue Biopharma announces collaboration with Merck "
    },
    {
        "content": "* Says \u200das of date of offers  aggregate outstanding principal amount of notes was about $2.95 billion\u200b",
        "date": "11132017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck announces pricing of any and all tender offers "
    },
    {
        "content": "* Merck & Co Inc - \u200doffers expired at 5:00 p.m.  New York City time  on Nov. 13  2017\u200b",
        "date": "11142017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck reports final results of any and all tender offers "
    },
    {
        "content": "Merck & Co Ltd's drug to prevent serious infection in patients who undergo a type of stem cell transplant was approved by the U.S. Food and Drug Administration  the drugmaker said on Thursday.",
        "date": "11092017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "FDA OKs Merck drug that prevents infection post-stem cell transplant "
    },
    {
        "content": "Nov 9 Merck & Co Ltd's drug to prevent serious infection in patients who undergo a type of stem cell transplant was approved by the U.S. Food and Drug Administration  the drugmaker said on Thursday.",
        "date": "11092017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 1-FDA OKs Merck drug that prevents infection post-stem cell transplant "
    },
    {
        "content": "Nov 9 Merck & Co Ltd's drug to prevent serious infection in patients who undergo a type of stem cell transplant was approved by the U.S. Food and Drug Administration  the drugmaker said on Thursday.",
        "date": "11092017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "FDA OKs Merck drug to stop infection post-stem cell transplant "
    },
    {
        "content": "* Merck receives FDA approval of Prevymis (letermovir) for prevention of cytomegalovirus (CMV) infection and disease in adult allogeneic stem cell transplant patients",
        "date": "11092017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck receives FDA approval of Prevymis for prevention of CMV infection in allogeneic stem cell transplant patients "
    },
    {
        "content": "* Merck & Co Inc says in July 2017  co learned that the prosecution office of Milan  Italy is investigating certain interactions - SEC filing",
        "date": "11072017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck & Co updates on investigation of co's Italian unit "
    },
    {
        "content": "Massachusetts' top court on Monday weighed whether the makers of brand name drugs like Merck & Co Inc can be sued over injuries blamed not on their own products but generic versions of the drugs other companies made.",
        "date": "11062017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Top Massachusetts court weighs Merck case over generic drug injury "
    },
    {
        "content": "* Merck & Co Inc - \u200dOffers are being made upon  and are subject to  terms and conditions set forth in offer to purchase  dated Nov. 6  2017\u200b",
        "date": "11062017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck announces any and all tender offers "
    },
    {
        "content": "Oct 30 U.S. stocks pulled back from record-high territory on Monday  weighed down by a drop in Merck shares  as investors assessed President Donald Trump's plan for corporate tax cuts.",
        "date": "10302017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "US STOCKS SNAPSHOT-Wall St ends lower; Merck  Trump tax talk weigh "
    },
    {
        "content": "* Indexes down: Dow 0.36 pct  S&P 0.32 pct  Nasdaq 0.03 pct (Updates with close of U.S. market)",
        "date": "10302017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "US STOCKS-Wall St slips as Merck drops  tax talk rattles "
    },
    {
        "content": "NEW YORK  Oct 30 A setback for Merck & Co's key cancer drug sent the drugmaker's stock swooning on Monday for a second straight session  putting the shares on track for their biggest two-day decline in more than eight years.",
        "date": "10302017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Cancer-drug setback sends Merck shares down again "
    },
    {
        "content": "NEW YORK  Oct 30 A setback for Merck & Co's key cancer drug sent the drugmaker's stock swooning on Monday for a second straight session  putting the shares on track for their biggest two-day decline in more than eight years.",
        "date": "10302017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 1-Cancer-drug setback sends Merck shares down again "
    },
    {
        "content": "Oct 26 Bristol-Myers Squibb Co reported a 7 percent increase in third-quarter revenue as sales of key drugs met Wall Street expectations  but earnings fell short due to higher costs and an inventory write-off  sending shares down 4 percent.",
        "date": "10262017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 1-Bristol-Myers sales in line  but profit margins worsen "
    },
    {
        "content": "Merck & Co  on Friday said quarterly sales of its Keytruda cancer immunotherapy exceeded $1 billion for the first time  but it withdrew an application for European use of the drug in lung cancer  raising questions about future sales.",
        "date": "10272017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck Keytruda sales soar  but European application pulled "
    },
    {
        "content": "Oct 27 Merck & Co on Friday said quarterly sales of its Keytruda cancer immunotherapy exceeded $1 billion for the first time  but it withdrew an application for European use of the drug in lung cancer  raising questions about future sales.",
        "date": "10272017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 4-Merck Keytruda sales soar  but European application pulled "
    },
    {
        "content": "Oct 27 Merck & Co Inc said on Friday it had withdrawn its European application for Keytruda as a combination treatment for patients with an advanced stage of non-small cell lung cancer.",
        "date": "10272017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck withdraws marketing application for Keytruda in Europe "
    },
    {
        "content": "* Merck provides update on European application for Keytruda (pembrolizumab) in combination with pemetrexed and carboplatin for first-line treatment of nonsquamous non-small cell lung cancer (NSCLC)",
        "date": "10272017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck withdraws European application for Keytruda "
    },
    {
        "content": "* Merck & Co CFO says cyber attack will have similar impact on Q4 results as outlined in Q3",
        "date": "10272017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck says cyber attack to impact fourth quarter results "
    },
    {
        "content": "* Q3 earnings per share view $1.03 -- Thomson Reuters I/B/E/S",
        "date": "10272017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck reports Q3 loss per share of $0.02 "
    },
    {
        "content": "Oct 27 Merck & Co reported a quarterly loss compared with a year-ago profit on Friday  hurt by a charge related to the formation of a collaboration with AstraZeneca Plc .",
        "date": "10272017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck posts quarterly loss vs. year-ago profit "
    },
    {
        "content": "* AstraZeneca and Merck rapidly advance LYNPARZA (olaparib) in Japan with a second regulatory submission",
        "date": "10232017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-AstraZeneca and Merck advance LYNPARZA in Japan with a second regulatory submission "
    },
    {
        "content": "LONDON  Oct 25 The committee responsible for U.S. vaccination schedules has given a preferential recommendation to GlaxoSmithKline's newly approved shingles vaccine Shingrix over Merck & Co's established product Zostavax.",
        "date": "10252017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "U.S. committee recommends GSK shingles vaccine over Merck rival "
    },
    {
        "content": "* \u200dASTRAZENECA AND MSD RAPIDLY ADVANCE LYNPARZA IN JAPAN WITH A SECOND REGULATORY SUBMISSION\u200b",
        "date": "10232017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-AstraZeneca and Merck submit application for breast cancer drug in Japan "
    },
    {
        "content": "LONDON  Oct 25 The committee responsible for U.S. vaccination schedules has given a preferential recommendation to GlaxoSmithKline's newly approved shingles vaccine Shingrix over Merck & Co's established product Zostavax.",
        "date": "10252017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 1-U.S. committee recommends GSK shingles vaccine over Merck rival "
    },
    {
        "content": "Drugmaker Merck & Co Inc   moving to a new sales team structure in the United States  plans to cut 1 800 sales positions  while adding 960 jobs to a new chronic care sales force  the company said on Friday.",
        "date": "10202017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck to cut 1 800 U.S. sales jobs  add 960 in chronic care "
    },
    {
        "content": "Oct 25 Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP)  responsible for U.S. vaccination schedules:",
        "date": "10252017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-ACIP votes 8-7 to prefer GSK's shingles vaccine Shingrix over Merck's Zostavax "
    },
    {
        "content": "Oct 20 Drugmaker Merck & Co Inc  moving to a new sales team structure in the United States  plans to cut 1 800 sales positions  while adding 960 jobs to a new chronic care sales force  the company said on Friday.",
        "date": "10202017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 1-Merck to cut 1 800 U.S. sales jobs  add 960 in chronic care "
    },
    {
        "content": "NEW YORK Insurers could pay $275 million to cover the insured portion of drugmaker Merck & Co's loss from a cyber attack in June  according to a forecast by Verisk Analytics Inc's Property Claim Services (PCS) unit.",
        "date": "10192017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck cyber attack may cost insurers $275 million: Verisk's PCS "
    },
    {
        "content": "Oct 20 Drugmaker Merck & Co Inc  moving to a new sales team structure in the United States  plans to cut 1 800 sales positions  while adding 960 jobs to a new chronic care sales force  the company said on Friday.",
        "date": "10202017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck to cut 1 800 U.S. sales jobs  add 960 jobs in chronic care "
    },
    {
        "content": "NEW YORK  Oct 19 Insurers could pay $275 million to cover the insured portion of drugmaker Merck & Co's loss from a cyber attack in June  according to a forecast by Verisk Analytics Inc's Property Claim Services (PCS) unit.",
        "date": "10192017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "CORRECTED-Merck cyber attack may cost insurers $275 mln -Verisk's PCS "
    },
    {
        "content": "* U.S. FDA accepts regulatory submission for lynparza\u00ae (olaparib) in metastatic breast cancer and grants priority review",
        "date": "10182017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-U.S. FDA accepts regulatory submission for lynparza "
    },
    {
        "content": "* Aeglea Biotherapeutics announces clinical collaboration with Merck to evaluate the combination of Aeglea\u2019S AEB1102 (pegzilarginase) with Merck's Keytruda\u00ae (pembrolizumab) for the treatment of small cell lung cancer",
        "date": "10162017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Aeglea Biotherapeutics announces clinical collaboration with Merck "
    },
    {
        "content": "* Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) more than doubled median overall survival compared to chemotherapy after two years of follow up in first-line treatment of patients with metastatic non-small cell lung cancer with high levels of PD-L1",
        "date": "10182017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck announces updated overall survival findings from Phase 3 trial of KEYTRUDA "
    },
    {
        "content": "LONDON  Oct 18 U.S. regulators have granted a priority review to AstraZeneca's ovarian cancer drug Lynparza as a treatment for breast cancer  putting it on track for potential approval in the new disease area during the first quarter of 2018.",
        "date": "10182017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Astra and Merck win speedy review for Lynparza in breast cancer "
    },
    {
        "content": "* Kalvista Pharmaceuticals announces collaboration with Merck",
        "date": "10102017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Kalvista Pharmaceuticals announces collaboration with Merck "
    },
    {
        "content": "Oct 11 Merck & Co Inc said on Wednesday it will not seek regulatory approval for its experimental cholesterol drug  anacetrapib  as the clinical profile of the treatment does not support regulatory filings.",
        "date": "10112017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck says will not seek approval of cholesterol treatment "
    },
    {
        "content": "* Merck & Co Inc - \u200dDecision follows a thorough review of clinical profile of Anacetrapib  including discussions with external experts\u200b",
        "date": "10112017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck provides update on Anacetrapib development program "
    },
    {
        "content": "A U.S. judge on Friday upheld a Merck & Co Inc patent on its antifungal drug Noxafil against a challenge by Teva Pharmaceutical Industries Ltd  which had sought to sell a generic version of the drug.",
        "date": "10022017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Judge upholds patent on Merck's antifungal drug Noxafil "
    },
    {
        "content": "LYON  France French police searched German drugmaker Merck KGaA's plant in Lyon on Tuesday as part of an investigation into complaints by patients about changes to its thyroid drug Levothyrox  a company spokeswoman said.",
        "date": "10032017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Police search Merck KGaA's French plant in thyroid pill inquiry "
    },
    {
        "content": "LYON  France  Oct 3 French police searched German drugmaker Merck KGaA's plant in Lyon on Tuesday as part of an investigation into complaints by patients about changes to its thyroid drug Levothyrox  a company spokeswoman said.",
        "date": "10032017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "REFILE-Police search Merck KGaA's French plant in thyroid pill inquiry "
    },
    {
        "content": "LONDON  Oct 5 Roche's immunotherapy drug Tecentriq has lost market share to Merck & Co's rival Keytruda since a clinical trial showed the Swiss company's medicine failed to improve overall survival in bladder cancer.",
        "date": "10052017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Roche bladder cancer drug struggles as medics focus on survival "
    },
    {
        "content": "Sept 29 U.S. drugmaker Merck & Co said on Friday it would discontinue developing an experimental drug combination for chronic hepatitis C  as competition rises and patient population shrinks.",
        "date": "09292017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck to stop development of hepatitis C treatments "
    },
    {
        "content": "* Merck discontinues MK-3682B and MK-3682C development programs",
        "date": "09292017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck discontinues MK-3682B and MK-3682C development programs "
    },
    {
        "content": "* Fda approves Merck\u2019s keytruda\u00ae (pembrolizumab) for previously treated patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer whose tumors express pd-l1 (cps greater than or equal to 1)",
        "date": "09222017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck says FDA approves Keytruda(pembrolizumab) for previously treated patients "
    },
    {
        "content": "* Merck announces findings from phase 3 study of KEYTRUDA (pembrolizumab)  compared to standard of care  in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma",
        "date": "09112017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck announces findings from phase 3 study of KEYTRUDA "
    },
    {
        "content": "* Now available in Canada: Isentress HD (raltegravir)  a new once-daily option  in combination with other antiretroviral agents  for the treatment of HIV-1 infection in appropriate patients",
        "date": "09122017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck says Isentress HD now available in Canada "
    },
    {
        "content": "FRANKFURT U.S. pharma group Merck & Co  has acquired 3-1/2 year old German biotech start-up Rigontec for up to 464 million euros ($554 million)  adding a new approach to its development of drugs that spur the immune system to attack tumors.",
        "date": "09062017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck & Co snaps up three year-old German biotech firm for up to $550 million "
    },
    {
        "content": "Sept 6 The U.S. Food and Drug Administration has placed a partial hold on three clinical trials testing Bristol-Myers Squibb's immunotherapy Opdivo in combination with other medicines for multiple myeloma due to risks seen in similar studies involving a rival drug  the company said on Wednesday.",
        "date": "09062017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Bristol-Myers says FDA places partial hold on Opdivo myeloma trials "
    },
    {
        "content": "FRANKFURT  Sept 6 U.S. pharma group Merck & Co has acquired 3-1/2 year old German biotech start-up Rigontec for up to 464 million euros ($554 million)  adding a new approach to its development of drugs that spur the immune system to attack tumours.",
        "date": "09062017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck & Co snaps up 3 yr-old German biotech firm for up to $550 mln "
    },
    {
        "content": "* European Commission approves Merck\u2019s KEYTRUDA (pembrolizumab) for the treatment of certain patients with locally advanced or metastatic urothelial carcinoma  a type of bladder cancer",
        "date": "09052017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-European Commission approves Merck\u2019S KEYTRUDA (pembrolizumab) "
    },
    {
        "content": "* Merck announces results of REVEAL outcomes study of Anacetrapib  investigational medicine for cardiovascular disease",
        "date": "08292017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck announces results of REVEAL outcomes study of Anacetrapib "
    },
    {
        "content": "Aug 29 A large study of Merck & Co Inc's experimental cholesterol drug anacetrapib found that it cut the risk of heart attack and death by a modest 9 percent  which could be due to its affect on bad LDL cholesterol  researchers said on Tuesday.",
        "date": "08292017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck cholesterol drug cuts heart risk by 9 pct in study "
    },
    {
        "content": "CHARLOTTESVILLE  Va./WASHINGTON U.S. President Donald Trump denounced neo-Nazis and the Ku Klux Klan as criminals and thugs on Monday  bowing to mounting political pressure to condemn such groups explicitly after a white-nationalist rally turned deadly in Virginia. |\u00a0Video ",
        "date": "08152017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Trump yields to pressure  calls neo-Nazis and KKK criminals "
    },
    {
        "content": "The U.S. Food and Drug Administration on Thursday expanded the use of Lynparza  sold by AstraZeneca Plc and Merck & Co Inc  to include ongoing treatment of patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy.",
        "date": "08172017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "FDA expands use of AstraZeneca/Merck ovarian cancer drug "
    },
    {
        "content": "The chief executives of Intel Corp  Merck & Co Inc and Under Armour Inc resigned from U.S. President Donald Trump's American Manufacturing Council on Monday  following Trump's initially tepid response to weekend violence at a rally of white supremacists in Charlottesville  Virginia. |\u00a0Video ",
        "date": "08152017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Three CEOs resign from Trump council over Charlottesville "
    },
    {
        "content": "Aug 17 The U.S. Food and Drug Administration on Thursday expanded the use of Lynparza  sold by AstraZeneca Plc and Merck & Co Inc  to include ongoing treatment of patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy.",
        "date": "08172017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 1-FDA expands use of AstraZeneca/Merck ovarian cancer drug "
    },
    {
        "content": "Aug 17 The U.S. Food and Drug Administration on Thursday expanded the use of Lynparza  sold by AstraZeneca Plc and Merck & Co Inc  to include ongoing treatment of patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy.",
        "date": "08172017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "FDA approves expanded use of AstraZeneca ovarian cancer drug "
    },
    {
        "content": "Aug 14 The chief executives of Intel Corp   Merck & Co Inc and Under Armour Inc resigned from U.S. President Donald Trump's American Manufacturing Council on Monday  following Trump's initially tepid response to weekend violence at a rally of white supremacists in Charlottesville  Virginia.",
        "date": "08152017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 10-Three CEOs resign from Trump council over Charlottesville "
    },
    {
        "content": "(The following statement was released by the rating agency) CHICAGO  August 17 (Fitch) Fitch Ratings has affirmed Merck & Co.  Inc.'s Issuer Default Rating (IDR) at 'A' with a Stable Rating Outlook. The ratings apply to roughly $28.4 billion of debt outstanding at June 30  2017. KEY RATING DRIVERS New Products/Growth Opportunities: Products approved during the last three years should help to drive intermediate- to long-term  top-line growth for Merck. Most importantly  Keytruda (cancer) is gaini",
        "date": "08172017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Fitch Affirms Merck at 'A'; Outlook Stable "
    },
    {
        "content": "Aug 14 Merck & Co Inc Chief Executive Kenneth Frazier resigned from U.S. President Donald Trump's American Manufacturing Council on Monday  saying he was taking a stand against intolerance and extremism.",
        "date": "08142017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "UPDATE 8-Merck CEO resigns from Trump council over Charlottesville "
    },
    {
        "content": "WASHINGTON U.S. President Donald Trump chided Merck & Co Inc's Kenneth Frazier after the drugmaker's chief executive resigned from a presidential advisory board earlier on Monday and cited a need for U.S. leaders to denounce bigotry following a violent weekend in Charlottesville  Virginia.",
        "date": "08142017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Trump chides Merck CEO after resignation from presidential council "
    },
    {
        "content": "WASHINGTON  Aug 14 U.S. President Donald Trump chided Merck & Co Inc's Kenneth Frazier after the drugmaker's chief executive resigned from a presidential advisory board earlier on Monday and cited a need for U.S. leaders to denounce bigotry following a violent weekend in Charlottesville  Virginia.",
        "date": "08142017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "REFILE-Trump chides Merck CEO after resignation from presidential council "
    },
    {
        "content": "Aug 14 Merck & Co Inc Chief Executive Kenneth Frazier resigned from U.S. President Donald Trump's American Manufacturing Council on Monday  saying he was taking a stand against intolerance and extremism.",
        "date": "08142017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "REFILE-UPDATE 1-Merck CEO resigns from Trump council after Charlottesville "
    },
    {
        "content": "* Merck & co says recently received investigative subpoena from california insurance commissioner\u2019s fraud liaison bureau - sec filing",
        "date": "08082017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck & Co says received investigative subpoena from california insurance commissioner\u2019s fraud liaison bureau - sec filing "
    },
    {
        "content": "* Merck CEO Kenneth Frazier says \"I am resigning from the president's American Manufacturing Council\" - tweet",
        "date": "08142017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck CEO Frazier says \"I am resigning from the president's American Manufacturing Council\" - tweet "
    },
    {
        "content": "* MSD Animal Health to purchase manufacturing facility in Krems  Austria",
        "date": "08072017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-MSD Animal Health to purchase manufacturing facility in Krems  Austria "
    },
    {
        "content": "Aug 3 Bristol-Myers Squibb Co said it would buy privately held IFM Therapeutics for an upfront payment of $300 million  as the drugmaker looks to bolster its cancer portfolio after losing ground to Merck & Co's rival treatment Keytruda.",
        "date": "08032017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Bristol-Myers to buy IFM Therapeutics to strengthen cancer pipeline "
    },
    {
        "content": "* Generex announces collaboration with Merck to evaluate keytruda (pembrolizumab) in combination with ae37 in patients with triple-negative breast cancer",
        "date": "07312017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Generex announces collaboration with Merck to evaluate Keytruda in combination with ae37 in patients with triple-negative breast cancer "
    },
    {
        "content": "* ASTRAZENECA AND MERCK ESTABLISH STRATEGIC ONCOLOGY COLLABORATION",
        "date": "07272017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Astrazeneca says establish strategic oncology collaboration with Merck "
    },
    {
        "content": "* Sets quarterly dividend of $0.47 per share Source text for Eikon: Further company coverage:",
        "date": "07252017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck sets quarterly dividend of $0.47 per share "
    },
    {
        "content": "* Merck's investigational NNRTI  doravirine  meets primary efficacy endpoint of non-inferiority to efavirenz  both in combination with other antiretroviral agents  in pivotal phase 3 trial for treatment of hiv-1 infection",
        "date": "07252017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck's investigational NNRTI  doravirine  meets primary efficacy endpoint "
    },
    {
        "content": "NEW YORK/LAS VEGAS Drug and vaccine maker Merck & Co Inc  said it suffered a worldwide disruption of its operations when it was the victim of an international cyber attack in June  halting production of its drugs  which will hurt its profits for the rest of the year.",
        "date": "07282017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck says cyber attack halted production  will hurt profits "
    },
    {
        "content": "July 24 Merck & Co said on Monday that its Keytruda immunotherapy failed to extend survival in previously treated patients with advanced head and neck cancer more than the standard combination therapy in a late-stage trial.",
        "date": "07242017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck immunotherapy fails to improve survival in head and neck cancer "
    },
    {
        "content": "* Co reiterates 2017 adjusted profit forecast (Adds conference call details  shares)",
        "date": "07282017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 3-AbbVie to remain cautious on drug pricing  shares fall "
    },
    {
        "content": "* Merck provides update on phase 3 study of keytruda\u00ae (pembrolizumab) monotherapy in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma (hnscc)",
        "date": "07242017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck provides update on phase 3 study of keytruda "
    },
    {
        "content": " (In this July 20 story  corrects to \"follow-on biologic\" from \"biosimilar\" in paragraphs 1  6 and 9; removes reference to \"biosimilar\" throughout the story.)",
        "date": "07242017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "FDA tentatively approves Merck's copycat of Sanofi's Lantus "
    },
    {
        "content": "NEW YORK/LAS VEGAS  July 28 Drug and vaccine maker Merck & Co Inc said it suffered a worldwide disruption of its operations when it was the victim of an international cyber attack in June  halting production of its drugs  which will hurt its profits for the rest of the year.",
        "date": "07282017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 4-Merck says cyber attack halted production  will hurt profits "
    },
    {
        "content": "July 20 Merck and Co Inc said on Thursday the U.S. Food and Drug Administration (FDA) tentatively approved its follow-on biologic version of French drugmaker Sanofi SA's blockbuster diabetes treatment  Lantus.",
        "date": "07242017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "CORRECTED-FDA tentatively approves Merck's copycat of Sanofi's Lantus (July 20) "
    },
    {
        "content": "FRANKFURT  July 27 Bayer  which is buying U.S. seeds company Monsanto  cut its forecast for operating profit growth this year to below 10 percent after declines in sales of consumer health products in the United States and crop chemicals in Brazil.",
        "date": "07282017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "CORRECTED-UPDATE 1-Bayer cuts profit forecast after consumer health headache "
    },
    {
        "content": "NEW YORK/SEOUL Merck & Co and South Korea's Samsung Bioepis Co Ltd said on Monday they have begun selling a less expensive alternative version of Johnson & Johnson's rheumatoid arthritis drug Remicade in the United States  a move that should accelerate price declines for the big-selling medicine.",
        "date": "07242017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck  Samsung Bioepis launch discounted U.S. Remicade alternative "
    },
    {
        "content": "* Q2 earnings per share view $0.87 -- Thomson Reuters I/B/E/S",
        "date": "07282017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck reports Q2 non-GAAP earnings of $1.01/shr "
    },
    {
        "content": "WASHINGTON  July 20 President Donald Trump on Thursday announced a $500 million investment that Corning Inc is making with pharmaceutical giants Merck and Pfizer to manufacture a new kind of glass for injectable drug vials.",
        "date": "07202017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "UPDATE 1-Trump unveils companies' $500 million U.S. drug packaging project "
    },
    {
        "content": "WASHINGTON President Donald Trump on Thursday announced a $500 million investment that Corning Inc is making with pharmaceutical giants Merck and Pfizer to manufacture a new kind of glass for injectable drug vials.",
        "date": "07212017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Trump unveils companies' $500 million U.S. drug packaging project "
    },
    {
        "content": "NEW YORK/SEOUL  July 24 Merck & Co and South Korea's Samsung Bioepis Co Ltd said on Monday they have begun selling a less expensive alternative version of Johnson & Johnson's rheumatoid arthritis drug Remicade in the United States  a move that should accelerate price declines for the big-selling medicine.",
        "date": "07242017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 1-Merck  Samsung Bioepis launch discounted U.S. Remicade alternative "
    },
    {
        "content": "July 28 Merck & Co Inc reported a 61.5 percent jump in quarterly profit on Friday as demand jumped for its key immuno-oncology drug  Keytruda.",
        "date": "07282017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck profit soars 61.5 pct as Keytruda sales surge "
    },
    {
        "content": "Merck and Co Inc said on Thursday the U.S. Food and Drug Administration (FDA) tentatively approved its biosimilar version of French drugmaker Sanofi SA's blockbuster diabetes treatment  Lantus.",
        "date": "07202017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "FDA tentatively approves Merck's copycat of Sanofi's Lantus "
    },
    {
        "content": "* European Medicines Agency's CHMP recommends approval for Merck's Keytruda\u00ae (pembrolizumab) for the treatment of certain patients with locally advanced or metastatic urothelial carcinoma  a type of bladder cancer",
        "date": "07212017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-European Medicines Agency's CHMP recommends approval for Merck's Keytruda "
    },
    {
        "content": "* Merck announces U.S. Launch of Renflexis(infliximab-abda)  a biosimilar of remicade  for all eligible indications Source text for Eikon: Further company coverage:",
        "date": "07242017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck announces U.S. launch of Renflexis "
    },
    {
        "content": "* Merck announces week 96 results from Oncemrk  a study evaluating once-daily Isentress HD (raltegravir)  in combination with other antiretroviral agents  for the treatment of HIV-1 infection in appropriate patients",
        "date": "07242017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck announces week 96 results from Oncemrk "
    },
    {
        "content": "* Merck announces presentations of clinical and real-world data at the Alzheimer\u2019s Association International Conference Source text for Eikon: Further company coverage:",
        "date": "07172017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck announces presentations of clinical and real-world data at the Alzheimer\u2019s Association International Conference "
    },
    {
        "content": "* Merck announces U.S. FDA grants tentative approval for Lusduna\u2122 Nexvue\u2122 (insulin glargine injection)  a follow-on biologic basal insulin",
        "date": "07202017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck announces U.S. FDA grants tentative approval for Lusduna\u2122 Nexvue\u2122 "
    },
    {
        "content": "* Aduro Biotech- $2.0 million milestone payment under worldwide licensing deal with merck for work supporting preparation of ind for anti-cd27 antibody\u200b",
        "date": "07132017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Aduro Biotech reports $2 mln milestone payment under licensing deal with Merck "
    },
    {
        "content": "* PDS Biotechnology says has entered a clinical trial collaboration agreement with a subsidiary of Merck",
        "date": "07102017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-PDS Biotechnology enters a clinical trial collaboration agreement with a subsidiary of Merck "
    },
    {
        "content": "* New clinical trial collaboration agreement between its PDS Biotechnology Corporation and a subsidiary of Merck & Co.  Inc.\u200b Source text for Eikon: Further company coverage:",
        "date": "07102017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-NetScientific updates on clinical trial collaboration deal between PDS  unit of Merck & Co "
    },
    {
        "content": "* Merck to present new data from clinical trials evaluating Isentress HD (raltegravir) and investigational HIV therapies Doravirine and MK-8591 at IAS 2017",
        "date": "07062017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck to present new data from clinical trials at IAS 2017 "
    },
    {
        "content": "Merck & Co  said on Wednesday the U.S. Food and Drug Administration had placed a clinical hold on three multiple myeloma studies testing its Keytruda in combination with other medicines for the blood cancer after more deaths were reported in patients receiving the Merck immunotherapy.",
        "date": "07062017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "FDA puts hold on Merck multiple myeloma trials after deaths "
    },
    {
        "content": "July 5 Merck & Co said on Wednesday the U.S. Food and Drug Administration had placed a clinical hold on three multiple myeloma studies testing its Keytruda in combination with other medicines for the blood cancer after more deaths were reported in patients receiving the Merck immunotherapy.",
        "date": "07052017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "UPDATE 1-FDA puts hold on Merck multiple myeloma trials after deaths "
    },
    {
        "content": "July 5 Merck & Co Inc said on Wednesday the U.S. Food and Drug Administration had placed a clinical hold on three multiple myeloma studies testing its immunotherapy drug  Keytruda  in combination with other therapies.",
        "date": "07052017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "FDA places clinical hold on Merck's combo therapy for multiple myeloma "
    },
    {
        "content": "* Merck provides further update on three multiple myeloma studies evaluating Keytruda\u00ae (pembrolizumab) in combination with pomalidomide or lenalidomide",
        "date": "07052017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck provides further update on 3 multiple myeloma studies evaluating Keytruda in combination with Pomalidomide  Lenalidomide "
    },
    {
        "content": "LONDON Novartis and Merck have both surprised experts in the past week by finding new ways to tackle heart disease  although the jury remains out as to whether this scientific success will translate into blockbuster sales.",
        "date": "06292017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Sales hopes for new Novartis  Merck heart drugs under microscope "
    },
    {
        "content": "* But questions over likely scale of clinical benefits (Recasts with sales forecasts and comments from experts)",
        "date": "06292017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 1-Sales hopes for new Novartis  Merck heart drugs under microscope "
    },
    {
        "content": "Merck & Co said on Tuesday its experimental cholesterol drug from a class with a history of consistent failure lowered deaths and heart attacks in a large trial  but the company has yet to decide whether to seek approval despite the surprise success.",
        "date": "06272017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck heart drug surprises with positive result; questions linger "
    },
    {
        "content": "June 27 Merck & Co said on Tuesday its experimental cholesterol drug from a class with a history of consistent failure lowered deaths and heart attacks in a large trial  but the company has yet to decide whether to seek approval despite the surprise success.",
        "date": "06272017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 2-Merck heart drug surprises with positive result; questions linger "
    },
    {
        "content": "* Merck provides update on reveal outcomes study of Anacetrapib",
        "date": "06272017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck provides update on reveal outcomes study of Anacetrapib "
    },
    {
        "content": "June 27 Merck & Co Inc said on Tuesday its cholesterol drug met its main goal of reducing coronary heart diseases in a late-stage study.",
        "date": "06272017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck's cholesterol drug clears main goal in late-stage study "
    },
    {
        "content": "* ABLYNX ACHIEVES SECOND MILESTONE IN IMMUNO-ONCOLOGY COLLABORATION WITH MERCK & CO.   INC.  KENILWORTH  NEW JERSEY  USA",
        "date": "06272017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Ablynx achieves second milestone in immuno-oncology collaboration "
    },
    {
        "content": "An appeals court handed biopharmaceutical company Gilead Sciences Inc a victory on Tuesday in its litigation with Merck & Co Inc over the blockbuster hepatitis C drug Sovaldi.",
        "date": "06212017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Gilead knocks out Merck patent on hepatitis C treatment "
    },
    {
        "content": "* Is entering a cooperation with Merck to develop technology applications for single-crystalline metal particles Source text for Eikon: Further company coverage:",
        "date": "06202017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-PV Nano Cell says cooperating with Merck for single-crystalline metal particles technology applications "
    },
    {
        "content": "* Human longevity - signed agreement with merck kgaa  darmstadt  germany which operates its biopharmaceutical business as emd serono in u.s. And canada",
        "date": "06152017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Human Longevity says agreement with Merck KGaA  Darmstadt  Germany to engage in cancer biomarker discovery in advanced melanoma "
    },
    {
        "content": "* Leap Therapeutics -  under agreement with unit of Merck  Co to sponsor and fund phase i/ii clinical trials of combination of dkn-01 and keytruda(reg)",
        "date": "06212017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Leap Therapeutics says Merck will sponsor and fund initial trials of their combo drug study "
    },
    {
        "content": "* Leap therapeutics announces collaboration with merck to evaluate keytruda\u00ae (pembrolizumab) in combination with dkn-01 in esophagogastric cancer",
        "date": "06212017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Leap Therapeutics announces collaboration with Merck "
    },
    {
        "content": "* Announced a research and development collaboration agreement with a subsidiary of Merck",
        "date": "06202017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Serimmune announces research  development collaboration agreement with subsidiary of Merck "
    },
    {
        "content": "Merck & Co said it paused enrolments in two late-stage studies testing its immunotherapy drug  Keytruda  for multiple myeloma  in combination with other therapies  as the U.S. drugmaker looks to better understand more reports of death in the Keytruda groups.",
        "date": "06122017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck to pause two late-stage studies testing Keytruda in myeloma "
    },
    {
        "content": "June 12 Merck & Co said it paused enrolments in two late-stage studies testing its immunotherapy drug  Keytruda  for multiple myeloma  in combination with other therapies  as the U.S. drugmaker looks to better understand more reports of death in the Keytruda groups.",
        "date": "06122017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 1-Merck to pause two late-stage studies testing Keytruda in myeloma "
    },
    {
        "content": "June 12 Merck & Co said on Monday it paused enrolments in two late-stage studies testing its immunotherapy drug Keytruda used in combination with other therapies to treat multiple myeloma  a type of blood cancer.",
        "date": "06122017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "CORRECTED-Merck to pause two late-stage studies testing Keytruda in myeloma "
    },
    {
        "content": "* Merck provides update on multiple myeloma studies keynote-183 and 185 of keytruda\u00ae (pembrolizumab) in combination with other therapies",
        "date": "06122017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck provides update on multiple myeloma studies keynote-183 and 185 of keytruda in combination with other therapies "
    },
    {
        "content": "LONDON  May 31 Britain's cost-effectiveness agency NICE has decided that Merck & Co's immunotherapy drug Keytruda can be used in previously untreated lung cancer patients under special funding arrangements.",
        "date": "05302017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Britain backs first-line use of Merck's Keytruda under cancer fund "
    },
    {
        "content": "* New data from phase 2 i-spy 2 trial shows improved outcomes with combination of Merck\u2019S Keytruda\u00ae (pembrolizumab) plus standard neoadjuvant therapy in patients with high-risk breast cancer",
        "date": "06052017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck presents positive mid-stage data from breast cancer combo therapy "
    },
    {
        "content": "* \u200dannounced updated longer-term overall survival (OS) data from Keynote-006  phase 3 study evaluating keytruda (pembrolizumab)\u200b",
        "date": "06022017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck announces updated longer-term overall survival data from evaluating keytruda "
    },
    {
        "content": "* Updated data from Echo-202 trial of Incyte\u2019s Epacadostat in combination with Merck\u2019s Keytruda\u00ae (Pembrolizumab) demonstrate clinical activity across multiple tumor types",
        "date": "06052017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Incyte Corp updates on Echo-202 trial of Incyte\u2019s Epacadostat in combination with Merck\u2019s Keytruda "
    },
    {
        "content": "* Merck announces presentation of phase 2 results for MK-7264  an investigational  p2x3 receptor antagonist  being evaluated for the treatment of chronic cough",
        "date": "05222017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck announces presentation of phase 2 results for MK-7264 "
    },
    {
        "content": "* Optum and merck collaborate to advance value-based contracting of pharmaceuticals",
        "date": "05252017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Optum and Merck collaborate to advance value-based contracting of pharmaceuticals "
    },
    {
        "content": "* NOVEL NANOBODY TO START CLINICAL DEVELOPMENT IN OSTEOARTHRITIS - ABLYNX TO RECEIVE \u20ac15 MILLION MILESTONE PAYMENT",
        "date": "05222017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Ablynx to receive 15 million euros milestone payment "
    },
    {
        "content": "* Merck enters exclusive worldwide license agreement with Teijin Pharma for investigational antibody candidate targeting TAU",
        "date": "05252017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck enters exclusive worldwide license agreement with Teijin Pharma "
    },
    {
        "content": "Merck & Co's immunotherapy Keytruda on Tuesday became the first cancer drug ever approved by the U.S. Food and Drug Administration based on a patients' specific genetic traits  regardless of where in the body the disease originated.",
        "date": "05232017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "FDA clears Merck's Keytruda based on cancer genetics  not location "
    },
    {
        "content": "May 23 Merck & Co's immunotherapy Keytruda on Tuesday became the first cancer drug ever approved by the U.S. Food and Drug Administration based on a patients' specific genetic traits  regardless of where in the body the disease originated.",
        "date": "05232017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 2-FDA clears Merck's Keytruda based on cancer genetics  not location "
    },
    {
        "content": "May 23 The U.S. Food and Drug Administration on Tuesday approved Merck & Co's immuno-oncology treatment  Keytruda  for cancer patients who carry a specific genetic feature.",
        "date": "05232017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "FDA clears Merck's Keytruda for cancer patients with certain biomarkers "
    },
    {
        "content": "LONDON  May 23 Britain's competition watchdog on Tuesday accused Merck & Co of operating an anti-competitive discount scheme for its medicine Remicade  designed to restrict competition from so-called biosimilar copies of the drug.",
        "date": "05232017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UK competition watchdog accuses Merck of obstructing biosimilars "
    },
    {
        "content": "* Sets quarterly dividend of $0.47 per share Source text for Eikon: Further company coverage:",
        "date": "05232017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck sets quarterly dividend of $0.47 per share "
    },
    {
        "content": "* CMA can fine companies up to 10 pct of global turnover (Adds details on past fines  more on biosimilars market)",
        "date": "05232017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 2-UK competition watchdog accuses Merck of obstructing biosimilars "
    },
    {
        "content": "* FDA grants priority review to Merck\u2019S supplemental biologics license application (sbla) for Keytruda\u00ae (pembrolizumab) for treatment of recurrent or advanced gastric or gastroesophageal junction adenocarcinoma",
        "date": "05232017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-FDA grants priority review to Merck's supplemental marketing application for Keytruda "
    },
    {
        "content": "* Merck receives chmp positive opinion recommending approval of isentress\u00ae (raltegravir) 600 mg in the european union",
        "date": "05192017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck receives CHMP positive opinion recommending approval of isentress "
    },
    {
        "content": "A combination of the Merck & Co immunotherapy Keytruda and a different type of drug that also helps the immune system fight cancer from Incyte Corp led to a high rate of durable responses in a small  ongoing study of patients with advanced lung cancer  according to data released on Wednesday.",
        "date": "05182017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck  Incyte immunotherapy combination effective in lung cancer study "
    },
    {
        "content": "Merck & Co Inc and Upsher-Smith Laboratories Inc have agreed to pay $60.2 million to resolve a lawsuit that said they  entered into a deal to unlawfully delay the availability of generic versions of potassium supplement K-Dur.",
        "date": "05162017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck  Upsher-Smith to pay $60 million in 'pay-for-delay' drug case "
    },
    {
        "content": "May 16 Merck & Co Inc and Upsher-Smith Laboratories Inc have agreed to pay $60.2 million to resolve a lawsuit that said they  entered into a deal to unlawfully delay the availability of generic versions of potassium supplement K-Dur.",
        "date": "05162017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck  Upsher-Smith to pay $60 mln in 'pay-for-delay' drug case "
    },
    {
        "content": "May 17 Pivotal trial results for Merck & Co Inc's immunotherapy drug Keytruda show that it lengthened survival by three months  or nearly 40 percent  for patients with advanced bladder cancer who had stopped responding to chemotherapy.",
        "date": "05172017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck says test shows Keytruda improves survival for bladder cancer patients "
    },
    {
        "content": "May 17 Pivotal trial results for Merck & Co Inc's immunotherapy drug Keytruda show that it lengthened survival by three months  or nearly 40 percent  for patients with advanced bladder cancer who had stopped responding to chemotherapy.",
        "date": "05172017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 1-Merck says test shows Keytruda improves survival for bladder cancer patients "
    },
    {
        "content": "May 17 A combination of the Merck & Co immunotherapy Keytruda and a different type of drug that also helps the immune system fight cancer from Incyte Corp led to a high rate of durable responses in a small  ongoing study of patients with advanced lung cancer  according to data released on Wednesday.",
        "date": "05172017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck  Incyte immunotherapy combination effective in lung cancer study "
    },
    {
        "content": "May 17 A combination of the Merck & Co immunotherapy Keytruda and a different type of drug that also helps the immune system fight cancer from Incyte Corp led to a high rate of durable responses in a small  ongoing study of patients with advanced lung cancer  according to data released on Wednesday.",
        "date": "05172017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 1-Merck  Incyte immunotherapy combination effective in lung cancer study "
    },
    {
        "content": "Merck & Co  said on Wednesday U.S. health regulators  approved its Keytruda in combination with chemotherapy for previously untreated advanced lung cancer  solidifying the drugmaker's lead position in the field of medicines that help the immune system fight cancer.",
        "date": "05112017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "U.S. FDA approves Merck immunotherapy/chemo combo for lung cancer "
    },
    {
        "content": "* Merck's Glucophage SR receives label extension for patients at high risk of type 2 diabetes in the UK Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)",
        "date": "05172017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck's Glucophage SR receives label extension for patients at high risk of type 2 diabetes in UK "
    },
    {
        "content": "* Aduro Biotech announces clinical collaboration with Merck to evaluate combination of Aduro's CRS-207 with Merck's Keytruda for treatment of Mesothelioma",
        "date": "05172017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Aduro Biotech announces clinical collaboration with Merck "
    },
    {
        "content": "May 10 Merck & Co said on Wednesday U.S. health regulators  approved its Keytruda in combination with chemotherapy for previously untreated advanced lung cancer  solidifying the drugmaker's lead position in the field of medicines that help the immune system fight cancer.",
        "date": "05102017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "UPDATE 2-U.S. FDA approves Merck immunotherapy/chemo combo for lung cancer "
    },
    {
        "content": "Merck & Co Inc and Upsher-Smith Laboratories Inc have agreed to pay $60.2 million to resolve a lawsuit that said they  entered into a deal to unlawfully delay the availability of generic versions of potassium supplement K-Dur.",
        "date": "05172017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck  Upsher-Smith to pay $60 mln in 'pay-for-delay' drug case "
    },
    {
        "content": "* Fda approves Merck's Keytruda\u00ae (pembrolizumab) as first-line combination therapy with pemetrexed and carboplatin for patients with metastatic nonsquamous non-small cell lung cancer (NSCLC)  irrespective of PD-l1 expression",
        "date": "05102017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-U.S. FDA approves Merck's Keytruda chemo combo for lung cancer "
    },
    {
        "content": "May 10 Merck & Co said on Wednesday that U.S. health regulators  approved its Keytruda in combination with chemotherapy for previously untreated advanced lung cancer  solidifying the drugmaker's lead position in the field of medicines that help the immune system fight cancer.",
        "date": "05102017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "U.S. FDA approves Merck immunotherapy/chemo combo for lung cancer "
    },
    {
        "content": "* European Commission grants approval for Merck's new Pergoveris\u00ae Pen for fertility treatment",
        "date": "05102017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-European Commission grants approval for Merck's new Pergoveris Pen for fertility treatment "
    },
    {
        "content": "* Oncosec announces clinical collaboration with Merck to evaluate combination of immunopulse IL-12 and keytruda(pembrolizumab) for metastatic melanoma",
        "date": "05102017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Oncosec announces clinical collaboration with Merck "
    },
    {
        "content": "* Cerveau Technologies Inc. Signs clinical supply agreement with merck for investigational tau imaging agent",
        "date": "05042017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Cerveau Technologies says finalization of a clinical supply agreement with Merck "
    },
    {
        "content": "Merck & Co Inc  on Tuesday reported better-than-expected profit in the first quarter as surprisingly strong demand for animal health products  vaccines and its hepatitis C treatment offset nearly $700 million in lower sales from drugs that lost patent protection.",
        "date": "05022017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck eyes key cancer drug growth as others lose patent protection "
    },
    {
        "content": "May 2 Merck & Co Inc on Tuesday reported better-than-expected profit in the first quarter as surprisingly strong demand for animal health products  vaccines and its hepatitis C treatment offset nearly $700 million in lower sales from drugs that lost patent protection.",
        "date": "05022017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 3-Merck eyes key cancer drug growth as others lose patent protection "
    },
    {
        "content": "* Merck & Co says expects growth in animal health to be \"more measured\" in subsequent quarters Source text for Eikon: Further company coverage: (Reporting By Bill Berkrot)",
        "date": "05022017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck expecting somewhat slower animal health growth "
    },
    {
        "content": "May 2 Merck & Co Inc reported a 1.3 percent rise in quarterly revenue  helped by higher demand for its key immuno-oncology drug Keytruda.",
        "date": "05022017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck's revenue rises 1.3 pct "
    },
    {
        "content": "U.S. regulators have approved AstraZeneca's key immunotherapy drug durvalumab as a treatment for bladder cancer  marking the first commercial green light for a product the company hopes will go on to sell billions of dollars.",
        "date": "05022017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "AstraZeneca immunotherapy wins first approval in bladder cancer "
    },
    {
        "content": "* AstraZeneca sets durvalumab price at $15 000/month (Adds analyst reaction  sales forecast  latest shares)",
        "date": "05022017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 3-AstraZeneca immunotherapy wins first approval in bladder cancer "
    },
    {
        "content": "* Syndax Pharmaceuticals announces expansion of encore 601/keynote 142  ongoing phase 2 clinical collaboration with a subsidiary of Merck",
        "date": "04272017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Syndax Pharmaceuticals announces expansion ongoing phase 2 collaboration with Merck unit "
    },
    {
        "content": "Merck & Co's cholesterol-reducing drug Vytorin faces competition for the first time ever after two companies announced progress on their generic versions of a drug that generated more than $1 billion in sales last year.",
        "date": "04262017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck cholesterol drug Vytorin faces competition from Impax  Teva generics "
    },
    {
        "content": "April 26 Merck & Co's cholesterol-reducing drug Vytorin faces competition for the first time ever after two companies announced progress on their generic versions of a drug that generated more than $1 billion in sales last year.",
        "date": "04262017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 1-Merck cholesterol drug Vytorin faces competition from Impax  Teva generics "
    },
    {
        "content": "April 26 The U.S. Food and Drug Administration on Wednesday approved Impax Laboratories Inc's generic version of Merck & Co's cholesterol-reducing drug Vytorin  the first cheap competitor for a drug that in 2016 generated more than $1 billion in sales.",
        "date": "04262017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "FDA approves Impax generic of Merck's cholesterol drug Vytorin "
    },
    {
        "content": "Merck & Co Inc has agreed to pay $19.5 million to resolve a lawsuit claiming its cancer immunotherapy drug Keytruda infringed a patent held by PDL BioPharma Inc.",
        "date": "04242017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck to pay PDL BioPharma $19.5 million to settle patent lawsuit "
    },
    {
        "content": "(The following statement was released by the rating agency) LONDON  April 26 (Fitch) Fitch Ratings says transactions by German healthcare group Fresenius SE & Co KGaA (FSE; BBB-/Stable) - including Fresenius Medical Care AG & Co. KGaA (FMC; together  Fresenius) - that enable its diversification into US generics through Akorn and biosimilars through Merck  will enhance its business risk profile. The group is well anchored in investment-grade territory  although the transactions will exhaust any f",
        "date": "04262017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Fitch: Fresenius Deals Offer Growth  Diversification; No Rating Impact "
    },
    {
        "content": "* PDL BioPharma announces settlement of Keytruda patent infringement lawsuit with Merck",
        "date": "04242017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-PDL BioPharma announces settlement of Keytruda lawsuit with Merck "
    },
    {
        "content": "* Real-World observational study in the U.S. Veterans Affairs System evaluating use of Merck\u2019S ZEPATIER\u00ae (Elbasvir and Grazoprevir) shows high sustained virologic response rates in patients with chronic Hepatitis C",
        "date": "04212017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck reports results from real-world observational study in U.S. Veterans Affairs System evaluating use of ZEPATIER "
    },
    {
        "content": "* Atara Bio announces collaboration with Merck to evaluate keytruda (pembrolizumab) in combination with ATA129 in nasopharyngeal carcinoma (NPC)",
        "date": "04212017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Atara bio announces collaboration with Merck "
    },
    {
        "content": "* Aurinia completes licensing deal with Merck Animal Health for its nanomicellar formulation of voclosporin for the treatment of canine dry eye syndrome",
        "date": "04172017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Aurinia completes licensing deal with Merck Animal Health "
    },
    {
        "content": "* Princess Margaret Cancer Center receives Health Canada clearance to begin investigator-sponsored phase 2 ovarian cancer study evaluating immunovaccine's DPX-survivac with Merck's pembrolizumab",
        "date": "04112017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Princess Margaret Cancer Center receives Health Canada clearance to begin investigator-sponsored phase 2 ovarian cancer study "
    },
    {
        "content": "* Merck & Co Inc - CEO Kenneth C. Frazier's 2016 total compensation was $21.8 million versus $24.2 million",
        "date": "04102017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck & Co Inc's CEO's 2016 total compensation was $21.8 mln "
    },
    {
        "content": "* Says its pharma unit receives license from US firm Merck & Co Inc for drug KRP-114V  a treatment for overactive bladder  owning exclusive rights to develop and commercialize in Asian area",
        "date": "04112017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-KYORIN Holdings unit gets license from Merck for drug KRP-114V "
    },
    {
        "content": "* Dr. John H. Noseworthy nominated to stand for election to Merck board of directors",
        "date": "04102017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck says board of directors to have 13 members "
    },
    {
        "content": "Merck & Co Inc is urging a U.S. appeals court to reconsider a ruling that revived hundreds of lawsuits accusing the company of failing to adequately warn about the risks of thigh bone fractures associated with its osteoporosis drug Fosamax.",
        "date": "04062017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck seeks to reverse ruling reviving Fosamax injury lawsuits "
    },
    {
        "content": "* Incyte and Merck provide additional details on previously announced collaboration investigating epacadostat and Keytruda\u00ae (pembrolizumab)",
        "date": "03312017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Incyte and Merck provide additional details on previously announced collaboration "
    },
    {
        "content": "A Pennsylvania foot doctor has agreed to pay nearly $123 000 to resolve charges he traded on inside information he received from a relative working at Merck & Co Inc about a planned merger  U.S. securities regulators said on Thursday.",
        "date": "03232017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck employee's relative settles SEC insider trading case "
    },
    {
        "content": "* European Medicines Agency's CHMP recommends approval of Merck's keytruda (pembrolizumab) for the treatment of patients with relapsed or refractory classical hodgkin lymphoma",
        "date": "03242017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-European Medicines Agency's CHMP recommends approval of Merck's keytruda "
    },
    {
        "content": "March 22 A federal appeals court on Wednesday revived hundreds of claims by plaintiffs who accused Merck & Co  of failing to adequately warn about the risks of thigh bone fractures associated with its osteoporosis drug Fosamax.",
        "date": "03222017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "U.S. appeals court revives Fosamax warning claims against Merck "
    },
    {
        "content": "A federal appeals court on Wednesday revived claims by several hundred plaintiffs who accused Merck & Co of failing to adequately warn about the risks of thigh bone fractures associated with its osteoporosis drug Fosamax.",
        "date": "03222017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck must face renewed Fosamax warning claims: U.S. appeals court "
    },
    {
        "content": "March 22 A federal appeals court on Wednesday revived claims by several hundred plaintiffs who accused Merck & Co of failing to adequately warn about the risks of thigh bone fractures associated with its osteoporosis drug Fosamax.",
        "date": "03222017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 3-Merck must face renewed Fosamax warning claims -U.S. appeals court "
    },
    {
        "content": "March 22 U.S. Appeals Court Revives Hundreds Of Claims Alleging Merck & Co",
        "date": "03222017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-U.S. appeals court revives claims against Merck over Fosamax "
    },
    {
        "content": "March 14 Merck & Co Inc said on Tuesday it had got a nod from the U.S. Food and Drug Administration for its already-approved immunotherapy drug Keytruda as a treatment for a type of blood cancer.",
        "date": "03142017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck's Keytruda wins FDA nod for treating blood cancer "
    },
    {
        "content": "* FDA approves Merck's Keytruda\u00ae (pembrolizumab) for adult and pediatric patients with classical hodgkin lymphoma (chl) refractory to treatment  or who have relapsed after three or more prior lines of therapy",
        "date": "03142017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck says FDA approves keytruda for treatment of patients with refractory classical hodgkin lymphoma "
    },
    {
        "content": "* Merck provides update on supplemental biologics license application (sbla) for keytruda\u00ae (pembrolizumab) in previously treated advanced microsatellite instability-high cancer",
        "date": "03142017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck provides update on supplemental biologics license application (sbla) for KEYTRUDA\u00ae (pembrolizumab) "
    },
    {
        "content": "* Merck and Pfizer announce U.S. Fda and EMA filing acceptances of 3 marketing applications for ertugliflozin-containing medicines for adults with type 2 diabetes",
        "date": "03062017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck and pfizer announce U.S. Fda and EMA filing acceptances "
    },
    {
        "content": "* Sets quarterly dividend of $0.47 per share  Source text for Eikon:  Further company coverage:",
        "date": "02282017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck sets quarterly dividend of $0.47/share "
    },
    {
        "content": "LONDON  Feb 28 Britain's healthcare watchdog NICE  which assesses the cost-effectiveness of medical treatments  has stopped short of recommending the use by the National Health Service (NHS) of Merck & Co Inc's immunotherapy drug Keytruda in newly diagnosed lung cancer patients  after giving the go-ahead in December for patients who had prior treatment.",
        "date": "02282017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UK rejects Merck's Keytruda as initial treatment for lung cancer "
    },
    {
        "content": "* In first phase 3 trial  Merck's investigational inactivated varicella zoster virus vaccine (V212) reduced the incidence of confirmed herpes zoster cases by an estimated 64 percent in immunocompromised subjects",
        "date": "02242017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-In first phase 3 trial Merck's virus vaccine (V2120 reduced the incidence of confirmed herpes zoster cases "
    },
    {
        "content": "* On Feb 17  determined that it will record intangible asset impairment charge related to research program for MK-3682  uprifosbuvir - SEC filing",
        "date": "02232017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck to record $2.9 bln impairment charge related to uprifosbuvir program - SEC filing "
    },
    {
        "content": "An experimental Merck & Co drug succeeded in preventing clinically serious cytomegalovirus (CMV) following bone marrow transplant and was associated with a lower death rate compared with placebo in a late state study  the company said.",
        "date": "02232017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck drug prevents serious infection after marrow transplant: study "
    },
    {
        "content": "* Biothera Pharmaceuticals initiates patient dosing in phase 2 trial investigating imprime pgg and merck\u2019s keytruda\u00ae (pembrolizumab)",
        "date": "02232017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Biothera Pharmaceuticals initiates patient dosing in phase 2 trial investigating Imprime PGG  Merck's Keytruda "
    },
    {
        "content": "* Capital World Investors reports 5.1 percent passive stake in Merck & Co Inc as on December 30  2016 - SEC Filing  Source text: [http://bit.ly/2kkIx8A] Further company coverage:",
        "date": "02132017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Capital World Investors reports 5.1 pct passive stake in Merck & Co as on Dec 30 - SEC Filing "
    },
    {
        "content": "Merck & Co Inc said on Tuesday it will halt a late-stage trial of an Alzheimer's drug after it was determined that it had no chance of working  marking the latest in a long line of crushing disappointments in efforts to find an effective treatment for the mind-wasting disease.",
        "date": "02142017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck stopping late stage study as another Alzheimer's drug fails "
    },
    {
        "content": "Feb 14 Merck & Co Inc said on Tuesday it will halt a late-stage trial of an Alzheimer's drug after it was determined that it had no chance of working  marking the latest in a long line of crushing disappointments in efforts to find an effective treatment for the mind-wasting disease.",
        "date": "02142017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 1-Merck stopping late stage study as another Alzheimer's drug fails "
    },
    {
        "content": "Feb 14 Merck & Co Inc said it would halt a late-stage trial of its drug in patients with mild to moderate Alzheimer's disease after an external panel pointed to a lack of effectiveness.",
        "date": "02142017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck to halt study of mild to moderate Alzheimer's drug "
    },
    {
        "content": "* Merck announces epoch study of verubecestat for the treatment of people with mild to moderate alzheimer's disease to stop for lack of efficacy",
        "date": "02142017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck announces Epoch study of Verubecestat "
    },
    {
        "content": "* Merck's doravirine  an investigational non-nucleoside reverse transcriptase inhibitor (nnrti) for the treatment of hiv-1 infection  met primary efficacy endpoint in pivotal phase 3 trial",
        "date": "02142017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck's doravirine meets primary efficacy endpoint in pivotal phase 3 trial "
    },
    {
        "content": "* Immunovaccine's lead immuno-oncology candidate to enter investigator-sponsored Phase 2 clinical trial in ovarian cancer in combination with approved anti-PD-1 drug",
        "date": "02062017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Immunovaccine says Princess Margaret Cancer Centre to conduct Phase 2 clinical trial to evaluate use of co  Merck's combination of immunotherapies "
    },
    {
        "content": "* FDA accepts two SBLAs for Merck's Keytruda\u007f (pembrolizumab) for locally advanced or metastatic urothelial cancer in cisplatin-ineligible first-line and second-line post-platinum failure treatment settings",
        "date": "02032017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck says FDA accepts two SBLAs for Keytruda "
    },
    {
        "content": "Merck & Co Inc   faced with patent expirations and increasing development costs for its high-profile Keytruda cancer immunotherapy  reassured investors on Thursday with a 2017 profit forecast roughly in line with Wall Street expectations. |\u00a0Video ",
        "date": "02022017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck 2017 forecast reassuring; full-speed ahead with Keytruda "
    },
    {
        "content": "Feb 2 Merck & Co Inc  faced with patent expirations and increasing development costs for its high-profile Keytruda cancer immunotherapy  reassured investors on Thursday with a 2017 profit forecast roughly in line with Wall Street expectations.",
        "date": "02022017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 3-Merck 2017 forecast reassuring; full-speed ahead with Keytruda "
    },
    {
        "content": "* European Commission approves Keytruda\u007f (pembrolizumab) for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-l1 expression with no EGFR or ALK positive tumor mutations",
        "date": "01312017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-European Commission approves Keytruda for first-line treatment of patients with metastatic non-small cell lung cancer "
    },
    {
        "content": "* Merck & Co CEO says business development a priority with focus on augmenting early and mid-stage pipeline",
        "date": "02022017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck CEO says business development a priority "
    },
    {
        "content": "Jan 31 U.S. securities class actions have soared to a two-decade high  topping levels during the financial crisis  after a landmark January 2016 ruling meant to deter lawsuits in Delaware that accomplish nothing for shareholders sent many lawyers scurrying instead to federal courts.",
        "date": "01312017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "U.S. securities class actions soar to two-decade high "
    },
    {
        "content": "Feb 2 - Merck & Co Inc reported a 1 percent drop in quarterly sales  hurt by a strong dollar and the loss of market exclusivity on certain drugs.",
        "date": "02022017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck's quarterly sales slip 1 pct "
    },
    {
        "content": "* Merck announces fourth-quarter and full-year 2016 financial results",
        "date": "02022017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck Q4 adjusted earnings per share $0.89 "
    },
    {
        "content": "Merck & Co  on Friday posted seven years of information showing a high single-digit percentage annual average price hike across its portfolio of medicines in a move that provides new details on its pricing practices for the U.S. market.",
        "date": "01272017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck reveals seven years of its U.S. drug price increase history "
    },
    {
        "content": "Jan 27 Merck & Co on Friday posted seven years of information showing a high single-digit percentage annual average price hike across its portfolio of medicines in a move that provides new details on its pricing practices for the U.S. market.",
        "date": "01272017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck reveals 7 years of its U.S. drug price increase history "
    },
    {
        "content": "ZURICH  Jan 27 Roche's cancer drug Tecentriq hit the market months behind immuno-oncology (I/O) medicines from Merck and Bristol-Myers Squibb Co  but the Swiss drugmaker's treatment is making up lost ground.",
        "date": "01272017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Roche cancer drug taking bite out of Bristol's Opdivo "
    },
    {
        "content": "* Says the co and BMS reached settlement and signed license agreement with Merck for patent infringement lawsuit against Merck  regarding anti-PD-1 antibody",
        "date": "01232017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Ono Pharmaceutical reaches settlement with Merck and signs license agreement "
    },
    {
        "content": "Jan 20 Merck & Co said it agreed to enter into a settlement and license agreement with Bristol-Myers Squibb Co and Ono Pharmaceutical Co Ltd to resolve a patent litigation related to its cancer drug  Keytruda.",
        "date": "01202017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck  Bristol-Myers agree to settle Keytruda patent suit "
    },
    {
        "content": "DAVOS  Switzerland Merck & Co's Keytruda cancer drug  which last week won a speedy review from U.S. regulators for use with chemotherapy in lung cancer  is in an increasingly strong position in a fiercely competitive market  the company's CEO said on Thursday.",
        "date": "01192017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck CEO sees Keytruda in pole position in cancer race "
    },
    {
        "content": "Jan 20 Merck & Co said it agreed to enter into a settlement and license agreement with Bristol-Myers Squibb Co and Ono Pharmaceutical Co Ltd to resolve all global patent-infringement litigation related to its cancer drug  Keytruda.",
        "date": "01202017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 1-Merck  Bristol-Myers agree to settle Keytruda patent suit "
    },
    {
        "content": "New YORK Bristol-Myers Squibb Co  shares fell 11 percent on Friday following Thursday's announcement that it would not seek accelerated approval of its immunotherapy drug combination in first-line lung cancer  further solidifying Merck & Co Inc's  leading position in the burgeoning immuno-oncolgy field.",
        "date": "01202017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Bristol-Myers lung cancer delay slams shares  keeps Merck in lead "
    },
    {
        "content": "New YORK  Jan 20 Bristol-Myers Squibb Co  shares fell 11 percent on Friday following Thursday's announcement that it would not seek accelerated approval of its immunotherapy drug combination in first-line lung cancer  further solidifying Merck & Co Inc's leading position in the burgeoning immuno-oncolgy field.",
        "date": "01202017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 1-Bristol-Myers lung cancer delay slams shares  keeps Merck in lead "
    },
    {
        "content": "NEW YORK  Jan 20 U.S. stocks closed higher on Friday in a modest but broad-based advance as Donald Trump was sworn in as U.S. President  marking the first time in more than 50 years that a new commander-in-chief has been welcomed by a rising equity market on his first day in office.",
        "date": "01202017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "US STOCKS-Wall St ends higher as Trump takes office "
    },
    {
        "content": "* Merck announces settlement and license agreement resolving Keytruda\u007f (pembrolizumab) patent litigation",
        "date": "01202017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck announces license agreement resolving Keytruda patent litigation "
    },
    {
        "content": "Merck & Co has pulled ahead of rivals in the race to combine immunotherapy with other drugs as a treatment for lung cancer  potentially giving it a major lift in the battle for the largest cancer market.",
        "date": "01112017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck leapfrogs rivals in lung cancer drug combination race "
    },
    {
        "content": "* Trump criticism helps snaps six-day rally for health stocks",
        "date": "01112017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "US STOCKS-Wall Street ends choppy session higher  health lags on Trump comments "
    },
    {
        "content": "Jan 10 Merck & Co on Tuesday said the FDA agreed to a speedy review of its application to combine its immunotherapy drug Keytruda with chemotherapy as an initial treatment for advanced lung cancer  potentially giving it a major leg up in the competition for the largest cancer market.",
        "date": "01102017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "FDA accepts Merck application for lung cancer combo therapy "
    },
    {
        "content": "* Incyte and Merck to advance clinical development program investigating the combination of Epacadostat with Keytruda\u007f (pembrolizumab)",
        "date": "01092017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Incyte and Merck to advance clinical development program investigating the combination of Epacadostat with Keytruda "
    },
    {
        "content": "* Move may put Merck ahead of AstraZeneca  Roche and Bristol   (Updates shares)",
        "date": "01112017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 2-Merck leapfrogs rivals in lung cancer drug combination race "
    },
    {
        "content": "* Merck receives fda acceptance of supplemental biologics license application for keytruda\u007f (pembrolizumab) in combination with chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer",
        "date": "01102017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck & Co Inc gets FDA acceptance of supplemental biologics license application for Keytruda in combination with chemotherapy "
    },
    {
        "content": "* Eli Lilly and co - financial details of collaboration were not disclosed.",
        "date": "01112017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Eli Lilly and Merck expand immuno-oncology collaboration "
    },
    {
        "content": "Merck & Co on Thursday was awarded $2.54 billion in royalties by a federal jury in a patent lawsuit against Gilead Sciences Inc over Gilead's blockbuster hepatitis C drugs Sovaldi and Harvoni.",
        "date": "12152016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck wins $2.54 billion in hepatitis C drug trial against Gilead "
    },
    {
        "content": "LONDON Britain's healthcare cost-effectiveness watchdog NICE has recommended use of Merck's immunotherapy drug Keytruda in certain lung cancer patients  after the U.S. drugmaker cut the price further for the state-run health service.",
        "date": "12022016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck wins UK okay for Keytruda in lung cancer after price cut "
    },
    {
        "content": "* FDA grants priority review to Merck's supplemental biologics license application (SBLA) seeking approval for Keytruda(pembrolizumab) for new indication in microsatellite instability-high cancer  Source text for Eikon:  Further company coverage:",
        "date": "11282016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-FDA grants priority review to Merck's supplemental biologics license application (SBLA) for Keytruda "
    },
    {
        "content": "Early next month  Gilead Sciences Inc will try to convince a federal jury in Delaware that a Merck & Co patent on hepatitis C drugs is invalid.",
        "date": "11282016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Gilead  Merck to face off before jury over hepatitis C drug patents "
    },
    {
        "content": "April 7 Merck & Co Inc said the U.S. Food and Drug Administration (FDA) declined an application to include information on the labels of its diabetes drugs - Januvia and Janumet - that the treatments do not raise the risk of major heart problems.",
        "date": "04072017",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "UPDATE 2-FDA rejects Merck's bid to add heart data on diabetes drug labels "
    },
    {
        "content": "Merck & Co said the U.S. Food and Drug Administration declined an application to include information on the labels of its diabetes drugs - Januvia and Janumet - that the treatments  do not raise the risk of major heart problems.",
        "date": "04072017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "FDA rejects Merck's application to add heart data on diabetes drug labels "
    },
    {
        "content": "April 7 Merck & Co said the U.S. Food and Drug Administration declined an application to include information on the labels of its diabetes drugs that the treatments do not raise the risk of major heart problems.",
        "date": "04072017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "FDA rejects Merck's application to add heart safety data on diabetes drug labels "
    },
    {
        "content": "* Merck receives complete response letter from the U.S. FDA for Tecos study with Sitagliptin",
        "date": "04072017",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck receives complete response letter from the FDA for Tecos study with sitagliptin "
    },
    {
        "content": "* Increased quarterly dividend to $0.47 per share  up $0.01 from $0.46 per outstanding share paid last quarter  Source text for Eikon:  Further company coverage:",
        "date": "11222016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck raises quarterly dividend to $0.47/share from $0.46/share "
    },
    {
        "content": "Gilead Sciences Inc has lost a bid to invalidate two Merck & Co patents on hepatitis C treatments  which Merck claims are infringed by Gilead's blockbuster Harvoni and Sovaldi.",
        "date": "11172016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Gilead loses bid to invalidate two Merck hepatitis C patents ahead of trial "
    },
    {
        "content": "* CEO says price pressure and competition for Erbitux in the EU will continue  Further company coverage:",
        "date": "11152016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck sees continued price pressure for Erbitux in the EU "
    },
    {
        "content": "* OpGen Inc - entered into research collaboration with Merck to develop rapid diagnostics  it products to help combat threat of antimicrobial resistance  Source text for Eikon:  Further company coverage:",
        "date": "11142016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-OpGen collaborates with Merck to develop rapid diagnostics and informatics tools to help combat antimicrobial resistance "
    },
    {
        "content": "* Biothera Pharmaceuticals' preclinical data further validate mechanism of its Phase 2 cancer immunotherapy  Imprime PGG",
        "date": "11112016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Biothera Pharma's announces new preclinical data on its immunotherapy drug "
    },
    {
        "content": "Nov 3 Two prominent U.S. lawmakers on Thursday called on federal antitrust regulators to probe whether Sanofi SA  Eli Lilly and Co  Merck & Co Inc  and Novo Nordisk A/S colluded to set prices for insulin and other diabetes drugs.",
        "date": "11042016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 5-Drugmakers under fire for possible U.S. price fixing "
    },
    {
        "content": "(The following statement was released by the rating agency) CHICAGO  October 27 (Fitch) (This is a correction of a release issued Oct. 27   2016. It clarifies that Merck's existing ratings were not affirmed as was stated  in the original release.)  Fitch Ratings has assigned an 'A' rating to Merck & Co.  Inc.'s (MRK/Merck) euro  notes offering. A complete list of ratings follows at the end of this press  release. KEY RATING DRIVERS The company's 'A' rating reflects the following: --Recently intr",
        "date": "10272016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Correction: Fitch Rates Merck's Euro Notes Offering 'A' "
    },
    {
        "content": "(The following statement was released by the rating agency) CHICAGO  October 27 (Fitch) Fitch Ratings has assigned an 'A' rating to Merck &  Co.  Inc.'s (MRK/Merck) euro notes offering. A complete list of ratings follows  at the end of this press release. KEY RATING DRIVERS The company's 'A' rating reflects the following: --Recently introduced therapies  an advancing pipeline and manageable patent  expiries should support intermediate- to long-term growth.  --Fitch believes that Merck will pursu",
        "date": "10272016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Fitch Rates Merck's Euro Notes Offering 'A' "
    },
    {
        "content": "* priced a EUR 1.0 billion public offering of two series of euro-denominated senior unsecured notes",
        "date": "10262016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck prices EUR 1 bln debt offering "
    },
    {
        "content": "* FDA approves Merck's KEYTRUDA\u007f (pembrolizumab) in metastatic NSCLC for first-line treatment of patients whose tumors have high PD-l1 expression (tumor proportion score  of 50 percent or more) with no EGFR or ALK genomic tumor aberrati",
        "date": "10242016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck & Co says FDA also approves a labeling update for Keytruda for treatment of patients with metastatic NSCLC "
    },
    {
        "content": "BRUSSELS  Oct 24 The following are mergers under review by the European Commission and a brief guide to the EU merger process:",
        "date": "10242016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "EU mergers and takeovers (Oct 24) "
    },
    {
        "content": "* Consensus forecasts point to $1.05 billion sales in 2021   (Adds sales forecast  background on rival vaccines)",
        "date": "10242016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 1-GSK files potential $1 bln shingles vaccine for U.S. approval "
    },
    {
        "content": "NEW YORK  Oct 25 - Merck & Co on Tuesday declared its intention to dominate the large and lucrative lung cancer market  bolstered by a significant expansion of approved U.S. uses for its drug that helps the immune system attack tumors.",
        "date": "10252016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "UPDATE 3-Merck predicts lung cancer dominance for Keytruda immunotherapy "
    },
    {
        "content": "Merck & Co Inc  reported better-than-expected quarterly revenue due to higher sales of its vaccines and cancer drug Keytruda  which won an early U.S. approval on Monday for use in previously untreated lung cancer patients.",
        "date": "10252016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck quarterly revenue beats  raises full-year forecast "
    },
    {
        "content": "Merck & Co Inc said its immunotherapy  Keytruda  helped previously treated patients with advanced bladder cancer live longer in a late-stage study  prompting an independent monitoring panel to recommend stopping the trial early.",
        "date": "10212016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck's Keytruda succeeds in key bladder cancer trial "
    },
    {
        "content": "* Advaxis initiates combination portion of phase 1/2 study with Merck",
        "date": "10202016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Advaxis initiates combination portion of phase 1/2 study with Merck "
    },
    {
        "content": "Merck & Co Inc said its experimental drug to prevent cytomegalovirus infection in high-risk bone marrow transplant patients met its primary goal in a late-stage trial.",
        "date": "10192016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck's antiviral drug meets main goal in late-stage trial "
    },
    {
        "content": "Oct 25 Merck & Co Inc :    Q3 non-gaap earnings per share $1.07",
        "date": "10252016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck & Co Q3 non-gaap EPS $1.07 "
    },
    {
        "content": "Oct 21 Merck & Co Inc said its immunotherapy  Keytruda  helped previously treated patients with advanced bladder cancer live longer in a late-stage study  prompting an independent monitoring panel to recommend stopping the trial early.",
        "date": "10212016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 1-Merck's Keytruda succeeds in key bladder cancer trial "
    },
    {
        "content": "BRUSSELS  Oct 20 The following are mergers under review by the European Commission and a brief guide to the EU merger process:",
        "date": "10202016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "EU mergers and takeovers (Oct 20) "
    },
    {
        "content": "Oct 19 Merck & Co Inc said its experimental drug to prevent cytomegalovirus infection in high-risk bone marrow transplant patients met its primary goal in a late-stage trial.",
        "date": "10192016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 1-Merck's antiviral drug meets main goal in late-stage trial "
    },
    {
        "content": "Oct 25 - Merck & Co Inc reported a 19.6 percent rise in quarterly net profit  driven primarily by higher demand for its new cancer drug Keytruda.",
        "date": "10252016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck reports 19.6 pct jump in quarterly profit "
    },
    {
        "content": "* Merck's keynote-045 studying Keytruda\u007f (pembrolizumab) in advanced bladder cancer (urothelial cancer) meets primary endpoint and stops early",
        "date": "10212016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck's bladder cancer drug meets primary endpoint and stops early "
    },
    {
        "content": "* Keeps full-year outlook   (Adds CEO  analyst comment  updates shares)",
        "date": "10202016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 2-Roche bets on new cancer drugs to offset patent expiries "
    },
    {
        "content": "* Merck announces pivotal phase 3 study of letermovir  an investigational antiviral medicine for prevention of cytomegalovirus (cmv) infection in high-risk bone marrow transplant patients  met primary endpoint",
        "date": "10192016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck says phase 3 study with Letermovir meets its primary endpoint "
    },
    {
        "content": "BRUSSELS  Oct 25 The following are mergers under review by the European Commission and a brief guide to the EU merger process:",
        "date": "10252016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "EU mergers and takeovers (Oct 25) "
    },
    {
        "content": "Oct 24 Merck & Co Inc on Monday said the U.S. Food and Drug Administration has approved its immunotherapy Keytruda for use in certain previously untreated lung cancer patients  making it the only approved first-line treatment.",
        "date": "10252016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "U.S. FDA approves Merck's lung cancer drug as first-line treatment "
    },
    {
        "content": "* Ablynx announces second extension of its Ion channel research collaboration with Merck & Co",
        "date": "10122016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Ablynx extends research collaboration with Merck & Co "
    },
    {
        "content": "* Aetna and Merck sign a unique value-based contract for Januvia and Janumet",
        "date": "10112016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Aetna and Merck sign a contract for Januvia and Janumet "
    },
    {
        "content": "New data is likely to prompt doctors to abandon Bristol-Myers Squibb's immunotherapy Opdivo in favor of Merck & Co's rival Keytruda in a large segment of the lucrative lung cancer market  analysts said on Monday.    The results of a closely watched clinical trial sent Bristol's shares plunging 10 percent.    The data  presented at a medical meeting on Sunday  showed that lung cancer patients fared worse on Opdivo than those on chemotherapy. Merck shares rose nearly 2 percent on stron",
        "date": "10112016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Bristol lung-cancer setback puts rival Merck drug in driver seat "
    },
    {
        "content": "A Delaware federal judge has invalidated Merck & Co Inc patent claims on its antibiotic Invanz in a challenge from rival Hospira Inc  which is seeking to sell a generic version of the drug.",
        "date": "10102016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Judge upholds Merck antibiotic patents against Hospira challenge "
    },
    {
        "content": "Oct 10 New data is likely to prompt doctors to abandon Bristol-Myers Squibb's immunotherapy Opdivo in favor of Merck & Co's rival Keytruda in a large segment of the lucrative lung cancer market  analysts said on Monday.",
        "date": "10102016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 1-Bristol lung-cancer setback puts rival Merck drug in driver seat "
    },
    {
        "content": "COPENHAGEN Merck & Co scored a double hit on Sunday with new clinical data showing its Keytruda immunotherapy offered big benefits in previously untreated lung cancer patients  either when given on its own or with chemotherapy.",
        "date": "10092016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "'New day' in lung cancer as Merck drug shines  works with chemo "
    },
    {
        "content": "The U.S. Supreme Court on Friday will consider a bid by drugmaker Merck & Co to change how a federal appeals court reviews decisions on patent validity made by the U.S. Patent and Trademark Office.",
        "date": "10072016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck asks justices to change how Federal Circuit reviews PTO trials "
    },
    {
        "content": "* Keytruda cuts risk of death 40 pct in big lung cancer study",
        "date": "10092016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck drug shines in lung cancer and also works with chemo "
    },
    {
        "content": "Bristol-Myers Squibb Co said on Tuesday it would evaluate the use of its blockbuster cancer immunotherapy Opdivo in combination with an experimental drug from Nektar Therapeutics to treat multiple cancers.",
        "date": "09272016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Bristol-Myers to test Opdivo with Nektar drug for several cancers "
    },
    {
        "content": "* Bayer says had underestimated risk from emerging markets volatility related to purchase of merck & co consumer care business",
        "date": "09202016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Bayer says Merck & Co integration disrupts business more than expected "
    },
    {
        "content": "* Bayer shares seen 1.5 pct higher   (Adds consumer care unit target  analyst comment  premarket share price)",
        "date": "09202016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 1-Bayer raises sales targets for top-selling drugs after Monsanto deal "
    },
    {
        "content": "* Files suit in  U.S. To defend paten rights on Lantus and Lantus Solostar",
        "date": "09192016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Sanofi files suit in U.S. to defend paten rights on Lantus and Lantus Solostar "
    },
    {
        "content": "* Merck presents new data examining durable efficacy with investigational cladribine tablets in multiple sclerosis",
        "date": "09162016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck presents new data examining durable efficacy with investigational cladribine tablets in multiple sclerosis "
    },
    {
        "content": "* Merck and pfizer announce investigational Ertugliflozin met primary endpoint of A1C reduction when added to Sitagliptin and Metformin in people with type 2 diabetes",
        "date": "09152016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck  Pfizer say investigational Ertugliflozin met primary endpoint "
    },
    {
        "content": "* Aralez acquires united states and canadian rights to Zontivity from Merck",
        "date": "09072016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Aralez acquires U.S.  Canadian rights to Zontivity from Merck "
    },
    {
        "content": "Merck & Co Inc said it would stop developing its experimental osteoporosis drug after an independent analysis confirmed the treatment raises the risk of stroke.",
        "date": "09022016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck scraps development of osteoporosis drug due to stroke risk "
    },
    {
        "content": "Sept 2 Merck & Co Inc said it would stop developing its experimental osteoporosis drug after an independent analysis confirmed the treatment raises the risk of stroke.",
        "date": "09022016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 1-Merck scraps development of osteoporosis drug due to stroke risk "
    },
    {
        "content": "* To discontinue development after independent adjudication of major adverse cardiovascular events confirmed an increased risk of stroke",
        "date": "09022016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck provides update on odanacatib development program "
    },
    {
        "content": "A federal judge in Delaware has struck down Merck & Co's patent infringement claims against Actavis' Warner Chilcott unit  which is seeking to sell a generic version of the NuvaRing contraceptive.",
        "date": "08302016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Judge invalidates Merck's NuvaRing patent claims "
    },
    {
        "content": "Sept 2 Merck & Co Inc said it would cease the development of its experimental osteoporosis drug after an independent analysis confirmed that the therapy was associated with an increased risk of stroke.",
        "date": "09022016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "REFILE-Merck aborts development of osteoporosis drug due to stroke risk "
    },
    {
        "content": "* Biothera pharmaceuticals expands relationship with Merck  enters collaboration for combination cancer immunotherapy trials in multiple indications  Source text for Eikon:  Further company coverage:",
        "date": "08242016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Biothera Pharmaceuticals expands relationship with Merck "
    },
    {
        "content": "Aug 11 Gilead Sciences Inc is entitled to receive the attorney fees it incurred related to hepatitis C patent litigation with drugmaker Merck & Co Inc  a U.S. district judge has ruled.",
        "date": "08122016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Gilead to get attorney fees in hepatitis C patent fight with Merck "
    },
    {
        "content": "* Based on its mechanism of action  Keytruda can cause fetal harm when administered to a pregnant woman",
        "date": "08082016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "CORRECTED-BRIEF-Merck & Co says FDA approves Keytruda for a type of head and neck cancer (Aug 5) "
    },
    {
        "content": "Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer  a major setback expected to benefit Merck & Co's rival medicine.",
        "date": "08052016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Bristol-Myers' Opdivo fails lung cancer trial; shares plunge "
    },
    {
        "content": "Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer  a major setback expected to benefit Merck & Co's  rival medicine.",
        "date": "08052016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge "
    },
    {
        "content": "LONDON AstraZeneca  shares hit a record high on Friday  breaching for the first time the 55 pounds a share level offered by Pfizer  in 2014 during the U.S. group's abortive $100 billion attempt to buy the drugmaker.",
        "date": "08052016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "AstraZeneca hits 2014 Pfizer bid price  helped by Bristol's woes "
    },
    {
        "content": "Aug 5 Merck Announces U.S. FDA Filing Acceptance Of New Drug Application (NDA) For Mk",
        "date": "08052016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck announces U.S. FDA filing acceptance of new drug application (NDA) for mk-1293 "
    },
    {
        "content": "* Merck's KEYTRUDA\u007f (pembrolizumab) approved by the European Commission for patients with advanced non-small cell lung cancer (nsclc) whose tumors express pd-l1  Source text for Eikon:  Further company coverage:",
        "date": "08022016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-European Commission approves Merck's anti-PD-1 therapy KEYTRUDA\u007f "
    },
    {
        "content": "NEW YORK Wall Street stocks fell on Tuesday  with each of the major indexes notching their worst day in about a month as economic data and weaker-than-expected auto sales spurred concerns about growth.",
        "date": "08022016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Wall St. falls as weak auto sales spur growth jitters "
    },
    {
        "content": "Aug 3 The following bids  mergers  acquisitions and disposals were reported by 2000 GMT on Wednesday:",
        "date": "08032016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Deals of the day-Mergers and acquisitions "
    },
    {
        "content": "A federal judge has declined to bar the plaintiffs' firm Sanford Heisler from soliciting potential collective action members in a sex discrimination lawsuit against Merck & Co Inc after the firm said it is not planning any more communications to solicit members  denying a motion on Friday by the drugmaker as moot.",
        "date": "08012016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck motion to bar plaintiff firm's communications denied as moot "
    },
    {
        "content": "* Indexes down: Dow 0.49 pct  S&P 0.64 pct  Nasdaq 0.9 pct   (Updates to market close)",
        "date": "08022016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "US STOCKS-Wall St falls as weak auto sales spur growth jitters "
    },
    {
        "content": "Aug 1 British quantum dots maker Nanoco Group Plc said it had entered into a non-exclusive licence deal with Merck for the German drugmaker to use its technology in digital displays  sending its shares up as much as 10 percent.",
        "date": "08012016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Nanoco signs deal with Merck for use of quantum dot technology "
    },
    {
        "content": "Aug 2 The following bids  mergers  acquisitions and disposals were reported by 2000 GMT on Tuesday:",
        "date": "08022016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Deals of the day- Mergers and acquisitions "
    },
    {
        "content": "Aug 2 Biotechnology giant Biogen Inc  has drawn takeover interest from drug companies including Merck & Co Inc and Allergan Plc  the Wall Street Journal reported  citing people familiar with the matter.",
        "date": "08022016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "REFILE-Biogen draws takeover interest from Merck  Allergan - WSJ "
    },
    {
        "content": "* Biogen has drawn takeover interest from drug companies including Merck & Co and Allergan Plc- WSJ  citing sources  Source (http://on.wsj.com/2b0s6q9)   (Bengaluru Newsroom: +1-646-223-8780)",
        "date": "08022016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Biogen has drawn takeover interest from drug companies including Merck & Co and Allergan - WSJ "
    },
    {
        "content": "Gilead Sciences Inc urged a California federal judge on Tuesday to not put off a decision on whether it is owed $15.5 million in legal fees in a patent fight over a lucrative cure for hepatitis C with drugmaker Merck & Co.",
        "date": "07282016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Gilead  Merck lock horns on legal fees in hepatitis C patent fight "
    },
    {
        "content": "Merck & Co  reported better-than-expected quarterly earnings  fueled by sales of its new Keytruda immuno-oncology drug and Januvia diabetes treatment  sending its shares up 2 percent in premarket trading.",
        "date": "07292016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck quarterly results beat forecasts  shares rise "
    },
    {
        "content": "Eli Lilly and Co said it received a civil investigative demand from the U.S. attorney's office for the southern district of New York  requesting documents and information relating to contracts with pharmacy benefit managers (PBMs).",
        "date": "07282016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "U.S. probes contracts between Eli Lilly and PBMs "
    },
    {
        "content": "July 29 Merck & Co reported better-than-expected quarterly earnings  fueled by sales of its new Keytruda immuno-oncology drug and Januvia diabetes treatment  sending its shares up 2 percent in premarket trading.",
        "date": "07292016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 2-Merck quarterly results beat forecasts  shares rise "
    },
    {
        "content": "July 29 Merck & Co Inc reported a 1 percent rise in quarterly revenue  driven by higher sales of its cancer drug  Keytruda.",
        "date": "07292016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck & Co reports 1 pct rise in quarterly revenue "
    },
    {
        "content": "July 28 Eli Lilly and Co said it received a civil investigative demand from the U.S. attorney's office for the southern district of New York  requesting documents and information relating to contracts with pharmacy benefit managers (PBMs).",
        "date": "07282016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 1-U.S. probes contracts between Eli Lilly and PBMs "
    },
    {
        "content": "Merck & Co Inc has asked a New Jersey federal judge to order law firm Sanford Heisler  which is representing plaintiffs in a sex discrimination lawsuit against the company  to stop what it called misleading communications to potential class members.",
        "date": "07282016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck seeks to curb plaintiff firm's 'misleading' communications "
    },
    {
        "content": "* Q2 januvia/janumet sales $ 1 634 million versus $1 412 million in q1",
        "date": "07292016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck Q2 adjusted earnings per share $0.93 "
    },
    {
        "content": "* Sets quarterly dividend of $0.46 per share  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",
        "date": "07262016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck sets quarterly dividend of $0.46 per share "
    },
    {
        "content": "* Collaboration focused on qualification and validation of Tau imaging agent developed by Merck  MK-6240",
        "date": "07252016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Enigma biomedical announces research collaboration agreement with Biogen Inc and Merck "
    },
    {
        "content": "* Said on Tuesday MSD (known as Merck in the United States and Canada) had informed ALK of its plans to end their partnership agreement",
        "date": "07272016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck plans to end partnership agreement with Alk Abello "
    },
    {
        "content": "* Merck is responsible for research  development  manufacturing  and regulatory efforts in support of v920",
        "date": "07252016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck designated breakthrough therapy by FDA and gets prime status from EMA for ebola vaccine "
    },
    {
        "content": "* Says European Medicines Agency (EMA) has accepted file for investigational once-daily formulation of isentress for review",
        "date": "07222016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck says EMA has accepted file for formulation of Isentress for review "
    },
    {
        "content": "U.S. Supreme Court Chief Justice John Roberts issued a stay on Thursday of an appeals court decision that would allow Actavis PLC to launch generic versions of Bayer AG's birth control drugs Safyral and Beyaz in response to an application from Bayer and Merck & Co.",
        "date": "07212016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Ruling invalidating Merck patent over on-sale bar stayed "
    },
    {
        "content": "* Fda has requested submission of new data and analyses from modify I and modify II clinical trials previously submitted",
        "date": "07212016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck provides regulatory update on Biologics application "
    },
    {
        "content": "LONDON British medical charity MRC Technology has pocketed $150 million by selling part of its royalty interest in Merck & Co's successful cancer drug Keytruda  allowing it to plough fresh funds into new research.",
        "date": "07142016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "UK charity pockets $150 million from Merck cancer immunotherapy drug "
    },
    {
        "content": "LONDON  July 15 British medical charity MRC Technology has pocketed $150 million by selling part of its royalty interest in Merck & Co's successful cancer drug Keytruda  allowing it to plough fresh funds into new research.",
        "date": "07142016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UK charity pockets $150 mln from Merck cancer immunotherapy drug "
    },
    {
        "content": "* Merck's Healthcare Services & Solutions invests in majority stake in Staywell",
        "date": "07112016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF- Merck's Healthcare invests majority stake in Staywell "
    },
    {
        "content": "* Merck KGaA and Pfizer initiate phase III trial to evaluate avelumab as first-line treatment for ovarian cancer",
        "date": "07072016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "REFILE-BRIEF-Pfizer and Germany's Merck KGaA initiate phase III trial "
    },
    {
        "content": "Merck & Co has appealed a California federal judge's order that overturned a $200 million verdict it won in a patent case against Gilead Sciences over Gilead's lucrative hepatitis C drugs on the grounds that Merck engaged in extensive misconduct.",
        "date": "07072016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck appeals order reversing its $200 mln verdict against Gilead "
    },
    {
        "content": "* Will acquire approximately 93 pct of shares of Vall\u00e9e S.A. at closing  in exchange for a payment of $400 mln",
        "date": "07012016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck Animal Health to buy controlling interest in Vall\u00e9e S.A "
    },
    {
        "content": "* Merck And Premier Inc collaborate to prevent fractures for osteoporosis patients",
        "date": "06302016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck  Premier Inc collaborate to improve care for osteoporosis patients "
    },
    {
        "content": "* Merck and Moderna announce strategic collaboration to advance novel MRNA-based personalized cancer vaccines with keytruda (pembrolizumab) for the treatment of multiple types of cancer  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1 646 223 8780)",
        "date": "06292016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck and Moderna announce strategic collaboration "
    },
    {
        "content": "Lawyers for longtime users of an osteoporosis drug will ask a federal appeals court on Thursday to revive their claims that Merck & Co.  Inc. waited too long to warn of the risk of unusual leg fractures associated with its use.",
        "date": "06302016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "3rd Circuit to weigh Fosamax warning lawsuits against Merck "
    },
    {
        "content": "Gilead Sciences Inc may have scored a dramatic and unexpected win over Merck & Co earlier this month in a patent dispute over the world's best-selling hepatitis C cure  but the war over this highly lucrative class of treatments has only just begun.",
        "date": "06292016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "After hepatitis C patent win over Merck  Gilead faces other foes "
    },
    {
        "content": "* Merck receives chmp positive opinion for keytruda\u007f (pembrolizumab) for the treatment of advanced non-small cell lung cancer (nsclc)",
        "date": "06272016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck receives CHMP positive opinion for Keytruda in advanced non-small cell lung cancer "
    },
    {
        "content": "* Phase 2 study of Relebactam  in combination with Imipenem/Cilastatin for complicated urinary tract infections met primary endpoint",
        "date": "06202016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck announces results of study of Relebactam  in combination with Imipenem/Cilastatin "
    },
    {
        "content": "June 16 Advanced lung cancer patients who took Merck & Co's Keytruda immuno-oncology medicine in a large trial and were previously untreated went longer without their disease worsening and showed a survival advantage over those given standard chemotherapy  the drugmaker said on Thursday.",
        "date": "06162016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck's Keytruda prolongs life in big lung-cancer study "
    },
    {
        "content": "June 16 Advanced lung cancer patients who took Merck & Co Inc's Keytruda immuno-oncology medicine in a large trial and were previously untreated went longer without their disease worsening and showed a survival advantage over those given standard chemotherapy  the drugmaker said on Thursday.",
        "date": "06162016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 1-Merck's Keytruda prolongs life in big lung-cancer study "
    },
    {
        "content": "* Merck's keytruda\u007f (pembrolizumab) demonstrates superior progression-free and overall survival compared to chemotherapy as first-line treatment in patients with advanced non-small cell lung cancer",
        "date": "06162016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck's Keytruda shows superior progression-free  overall survival in lung cancer patients "
    },
    {
        "content": "Merck & Co's experimental drug to treat the most common cause of hospital-associated infectious diarrhea warrants approval  an advisory panel to the U.S. Food and Drug Administration said on Thursday.",
        "date": "06092016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "U.S. panel backs approval for Merck infectious diarrhea drug "
    },
    {
        "content": "* Signed a definitive agreement under which Merck will acquire Afferent Pharmaceuticals",
        "date": "06092016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck to acquire Afferent Pharmaceuticals "
    },
    {
        "content": "* Agenus announces lead product candidate selection in its collaboration with Merck",
        "date": "06092016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Agenus announces lead product candidate selection in Merck collaboration "
    },
    {
        "content": "NEW YORK A U.S. judge on Monday found a pattern of misconduct by Merck & Co including lying under oath and other unethical practices  freeing Gilead Sciences Inc from paying any damages for infringing Merck's patents with its lucrative treatments for hepatitis C  Sovaldi and Harvoni.",
        "date": "06072016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Gilead escapes liability in hepatitis C patent fight with Merck "
    },
    {
        "content": "NEW YORK  June 6 A U.S. judge on Monday found a pattern of misconduct by Merck & Co including lying under oath and other unethical practices  freeing Gilead Sciences Inc from paying any damages for infringing Merck's patents with its lucrative treatments for hepatitis C  Sovaldi and Harvoni.",
        "date": "06072016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 2-Gilead escapes liability in hepatitis C patent fight with Merck "
    },
    {
        "content": "NEW YORK  June 6 A U.S. judge on Monday found a pattern of misconduct by Merck & Co including lying under oath and other unethical practices  freeing Gilead Sciences Inc from paying any damages for infringing Merck's patents with its lucrative treatments for hepatitis C  Sovaldi and Harvoni.",
        "date": "06072016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Gileads escapes liability in hepatitis C patent fight with Merck "
    },
    {
        "content": "* Shareholder proposal requesting report on disposal of unused or expired drugs was defeated at annual meeting",
        "date": "05272016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck shareholder proposal for report on disposal of unused or expired drugs defeated "
    },
    {
        "content": "* Merck receives positive CHMP opinion for Zepatier(tm) (Elbasvir and Grazoprevir) in the European Union  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",
        "date": "05272016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck receives positive CHMP opinion for Zepatier in the EU "
    },
    {
        "content": "* Sets quarterly dividend of $0.46 per share  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",
        "date": "05242016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck sets quarterly dividend of 46 cents per share "
    },
    {
        "content": "A Merck & Co patent on a crystallized form of a B vitamin is invalid because Merck offered to sell the formula to an American company in 1998  a federal appeals court has ruled  reversing a lower court judge.",
        "date": "05162016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck B vitamin formula patent invalid due to on-sale bar - Federal Circuit "
    },
    {
        "content": "* Merck to present Phase 3 data on investigational medicines Ertugliflozin and MK-1293 at the 76th scientific sessions of the American Diabetes Association  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",
        "date": "05122016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck to present Phase 3 data on Ertugliflozin and MK-1293 "
    },
    {
        "content": "* Says European launch of its new Zepatier hepatitis C drug may may be delayed until late 2016 or 2017 after EU regulator cited inadequate record-keeping by a third party manufacturer  Source text for Eikon:  Further company coverage:    (Reporting by Ransdell Pierson)",
        "date": "05052016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck says EU Zepatier launch may be delayed "
    },
    {
        "content": "* Says on conference call that third party manufacturer of its new Zepatier hepatitis C drug cited by EU regulators for inadquate record keeping",
        "date": "05052016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck says EU manufacturer of Zepatier cited for recordkeeping lapses "
    },
    {
        "content": "May 5 Merck & Co Inc on Thursday reported lower-than-expected quarterly revenue  hurt by disappointing sales of its Januvia diabetes treatment and Remicade arthritis drug.",
        "date": "05052016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "RPT-UPDATE 2-Merck sales disappoint as Januvia  Remicade fall short "
    },
    {
        "content": "Merck & Co Inc  on Thursday reported lower-than-expected quarterly revenue  hurt by disappointing sales of its Januvia diabetes treatment and Remicade arthritis drug.",
        "date": "05052016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck sales disappoint as Januvia  Remicade fall short "
    },
    {
        "content": "* Q1 earnings per share view $0.85 -- Thomson Reuters I/B/E/S",
        "date": "05052016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck Q1 earnings per share $0.40 "
    },
    {
        "content": "* Says phase III tailor landmark study  demonstrates  significant  benefits of erbitux in combination  with  folfox over folfox alone",
        "date": "04252016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck KGaA publishes Chinese Phase III study for Erbitux "
    },
    {
        "content": "A federal judge has granted preliminary approval for a lawsuit accusing Merck & Co Inc of underpaying female sales representatives to go forward as a collective action.",
        "date": "04282016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck sex discrimination case could be collective action: judge "
    },
    {
        "content": "April 27 A federal judge has granted preliminary approval for a lawsuit accusing Merck & Co Inc of underpaying female sales representatives to go forward as a collective action.",
        "date": "04272016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "UPDATE 1-Merck sex discrimination case could be collective action -judge "
    },
    {
        "content": "April 27 A federal judge has granted preliminary approval for a lawsuit accusing Merck & Co Inc of underpaying female sales representatives to go forward as a collective action.",
        "date": "04272016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck sex discrimination case could be collective action -judge "
    },
    {
        "content": "April 18 Merck Says  Fourth Designation For Keytruda Follows Breakthrough Status In Advanced Melanoma  Non",
        "date": "04182016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck receives breakthrough therapy designation from FDA for use of Keytruda in classical hodgkin lymphoma "
    },
    {
        "content": "* Merck Animal Health to acquire worldwide rights to Whisper\u007f Veterinary Stethoscope System",
        "date": "04192016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck Animal Health to buy worldwide rights to Whisper Veterinary Stethoscope System "
    },
    {
        "content": "* Says Merck launches Merck for Health project in partnership with H-Farm  Source text for Eikon:",
        "date": "04142016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck launches Merck for Health project in partnership with H-farm "
    },
    {
        "content": "* Merck & Co Inc says CEO Kenneth C. Frazier's total compensation for FY 2015 was $24.2 mln vs $25 mln in FY 2014 - SEC Filing",
        "date": "04112016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck & Co says CEO Kenneth C. Frazier's total compensation for 2015 was $24.2 MLN "
    },
    {
        "content": "Gilead Sciences Inc on Wednesday will attempt to wipe out $200 million in damages for infringing two Merck & Co patents with its blockbuster hepatitis C treatments by claiming that Merck was dishonest in obtaining the patents  an argument that attorneys say could be difficult to prove.",
        "date": "03292016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Gilead says Merck 'deceitful' in hepatitis C drug patent fight "
    },
    {
        "content": "SAN JOSE  Calif.  March 24 A federal jury on Thursday ordered Gilead Sciences Inc to pay Merck & Co  $200 million in damages for infringing two Merck patents related to a lucrative cure for hepatitis C.",
        "date": "03242016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Gilead ordered to pay Merck $200 mln in hepatitis C drug patent dispute "
    },
    {
        "content": "SAN JOSE  Calif. /NEW YORK A federal jury on Thursday ordered Gilead Sciences Inc to pay Merck & Co  $200 million in damages for infringing two Merck patents related to a lucrative cure for hepatitis C.",
        "date": "03252016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Gilead ordered to pay Merck $200 mln in hepatitis C drug patent dispute "
    },
    {
        "content": "SAN JOSE Merck & Co told a federal jury on Tuesday it was seeking more than $2 billion in damages from rival Gilead Sciences Inc after the jury upheld the validity of two Merck patents in a high-profile dispute over Gilead's blockbuster cure for hepatitis C.",
        "date": "03232016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck patents on Hepatitis C treatment found valid in Gilead dispute "
    },
    {
        "content": "SAN JOSE  Calif. /NEW YORK A federal jury on Thursday ordered Gilead Sciences Inc  to pay Merck & Co  $200 million in damages for infringing two Merck patents related to a lucrative cure for hepatitis C.",
        "date": "03252016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Gilead ordered to pay Merck $200 million in hepatitis C drug patent dispute "
    },
    {
        "content": "SAN JOSE  March 22 Merck & Co told a federal jury on Tuesday it was seeking more than $2 billion in damages from rival Gilead Sciences Inc after the jury upheld the validity of two Merck patents in a high-profile dispute over Gilead's blockbuster cure for hepatitis C.",
        "date": "03232016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 3-Merck patents on Hepatitis C treatment found valid in Gilead dispute "
    },
    {
        "content": "SAN JOSE  Calif. /NEW YORK  March 24 A federal jury on Thursday ordered Gilead Sciences Inc to pay Merck & Co $200 million in damages for infringing two Merck patents related to a lucrative cure for hepatitis C.",
        "date": "03252016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 3-Gilead ordered to pay Merck $200 mln in hepatitis C drug patent dispute "
    },
    {
        "content": "SAN JOSE A federal jury on Tuesday upheld the validity of two Merck & Co patents in a high-profile dispute with rival Gilead Sciences Inc  which could be forced to hand over a portion of the billions of dollars in revenue from its blockbuster cure for hepatitis C.",
        "date": "03222016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck patents on Hepatitis C treatment found valid in Gilead dispute "
    },
    {
        "content": "NEW YORK  March 22 A federal jury on Tuesday upheld the validity of two Merck & Co patents in a high-profile dispute with rival Gilead Sciences Inc  which could be forced to hand over a portion of the billions of dollars in revenue from its blockbuster cure for hepatitis C.",
        "date": "03222016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck patents on Hepatitis C treatment found valid in dispute with Gilead "
    },
    {
        "content": "* Has been designated as a reference laboratory for Merck Millipore for marketing of Milliplex technology used for biomarkers determination",
        "date": "03072016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Neuron Bio designated as reference laboratory for Merck Millipore "
    },
    {
        "content": "PARIS Sanofi SA and Merck & Co Inc said on Tuesday they were ending a 22-year-old joint venture to sell vaccines in Europe  arguing they would do better by managing their product portfolios independently.",
        "date": "03082016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Sanofi and Merck pull the plug on European vaccines venture "
    },
    {
        "content": "PARIS  March 8 Sanofi SA and Merck & Co Inc said on Tuesday they were ending a 22-year-old joint venture to sell vaccines in Europe  arguing they would do better by managing their product portfolios independently.",
        "date": "03082016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 1-Sanofi and Merck pull the plug on European vaccines venture "
    },
    {
        "content": "PARIS  March 8 Sanofi said on Tuesday that it was ending its joint vaccines operations in Europe with U.S partner Merck in order to allow both companies to pursue different strategies.",
        "date": "03082016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Sanofi Pasteur and Merck end European vaccines venture "
    },
    {
        "content": "FRANKFURT  March 8 The DAX top-30 index  looked set to open 0.6 percent lower on Tuesday  according to premarket data from brokerage Lang & Schwarz at 0716 GMT.",
        "date": "03082016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "German stocks - Factors to watch on March 8 "
    },
    {
        "content": "A federal judge has narrowed an antitrust class action brought by drug wholesalers alleging that Schering-Plough Corp  now owned by Merck  paid generic rivals to stay out of the market for its potassium supplement K-Dur.",
        "date": "02262016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Judge trims antitrust case against Merck over potassium drug "
    },
    {
        "content": "Feb 15 Drugmaker Merck & Co Inc said the U.S. Food and Drug Administration declined to approve its claim that cholesterol-lowering drugs Zetia and Vytorin reduce the risk of heart attacks and strokes in patients with coronary heart disease.",
        "date": "02162016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck says U.S. FDA reject its claim that Zetia and Vytorin cut heart risk "
    },
    {
        "content": "Merck & Co Inc  on Wednesday issued a cautious 2016 outlook and reported disappointing fourth-quarter sales of its Januvia diabetes treatment and its Remicade arthritis drug  sending its shares down nearly 3 percent.",
        "date": "02032016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck gives cautious 2016 outlook as sales of top medicines lag "
    },
    {
        "content": "Feb 3 Merck & Co Inc on Wednesday issued a cautious 2016 outlook and reported disappointing fourth-quarter sales of its Januvia diabetes treatment and its Remicade arthritis drug  sending its shares down nearly 3 percent.",
        "date": "02032016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 3-Merck gives cautious 2016 outlook as sales of top medicines lag "
    },
    {
        "content": "* Says it expects global Januvia/Janumet sales to rise in 2016  when excluding negative impact of strong dollar",
        "date": "02032016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck sees accelerating declines for Remicade  due to biosimilars "
    },
    {
        "content": "Feb 3 Merck & Co Inc reported a 2.5 percent fall in quarterly revenue  hurt by a strong dollar and declining sales of its Remicade arthritis treatment.",
        "date": "02032016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck revenue falls as dollar strengthens "
    },
    {
        "content": "Jan 29 U.S. pharmacy benefit managers expect the launch of Merck & Co Inc's new hepatitis C pill to improve their leverage in price negotiations with drugmakers.",
        "date": "01292016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Payers see price leverage with entry of Merck hepatitis C drug "
    },
    {
        "content": "Jan 28 U.S. regulators on Thursday approved a new once-daily treatment for the liver-destroying hepatitis C virus made by Merck & Co Inc.",
        "date": "01282016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "U.S. FDA approves Merck's new hepatitis C pill "
    },
    {
        "content": "U.S. regulators on Thursday approved a new once-daily pill for the liver-destroying hepatitis C virus made by Merck & Co Inc  which said it will sell the drug at a lower list price than its competitors.",
        "date": "01292016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "FDA approves Merck's new hepatitis C pill "
    },
    {
        "content": "Jan 28 U.S. regulators on Thursday approved a new once-daily pill for the liver-destroying hepatitis C virus made by Merck & Co Inc  which said it will sell the drug at a lower list price than its competitors.",
        "date": "01292016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 1-U.S. FDA approves Merck's new hepatitis C pill "
    },
    {
        "content": "Bristol-Myers Squibb Co  on Thursday positioned itself as a potential earnings pacesetter in 2016  with a forecast of up to 19 percent growth that eclipses profit gains expected by most other large drugmakers.",
        "date": "01282016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Bristol-Myers set to lead earnings parade in 2016  beyond "
    },
    {
        "content": "DAVOS  Switzerland U.S. drugmaker Merck & Co is eager to do deals to bring in promising experimental medicines and believes a recent correction in biotechnology stocks should throw up new opportunities.",
        "date": "01222016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck sees deal opportunities as biotech funding gets tighter "
    },
    {
        "content": "DAVOS/LONDON The Gavi global alliance for vaccines and immunization group signed a $5 million advance purchase commitment on Wednesday to buy a vaccine being developed by Merck to protect against future outbreaks of the deadly Ebola virus.",
        "date": "01202016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Vaccines alliance signs $5 million advance deal for Merck's Ebola shot "
    },
    {
        "content": "DAVOS/LONDON  Jan 20 The Gavi global alliance for vaccines and immunisation group signed a $5 million advance purchase commitment on Wednesday to buy a vaccine being developed by Merck to protect against future outbreaks of the deadly Ebola virus.",
        "date": "01202016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Vaccines alliance signs $5 mln advance deal for Merck's Ebola shot "
    },
    {
        "content": "FRANKFURT  Jan 15 Germany's Merck KGaA  said it won a British court's backing in its quest to keep U.S. namesake drugmaker Merck & Co Inc from doing business under the Merck name outside North America  part of an increasingly bitter legal feud.",
        "date": "01152016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Fight over Merck name sees German firm win in British court "
    },
    {
        "content": "Jan 15 U.S. drugmaker Merck & Co on Friday said it would pay $830 million to settle a federal class action lawsuit involving allegations the company failed to adequately inform investors about heart risks from its now-recalled Vioxx pain medication.",
        "date": "01152016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck agrees to pay $830 mln to settle Vioxx securities lawsuit "
    },
    {
        "content": "U.S. drugmaker Merck & Co on Friday said it would pay $830 million to settle a federal class action lawsuit involving allegations the company failed to adequately inform investors about heart risks from its now-recalled Vioxx pain medication.",
        "date": "01152016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck agrees to pay $830 million to settle Vioxx securities lawsuit "
    },
    {
        "content": "JERUSALEM  Jan 12 Israeli biopharmaceutical company BioLineRX Ltd said on Tuesday it would collaborate with U.S. industry heavyweight Merck to test a combination of drugs for the treatment of pancreatic cancer.",
        "date": "01122016",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck  BioLineRX to study drug combo to fight pancreatic cancer "
    },
    {
        "content": "* Biocartis and Merck to collaborate on new liquid biopsy technology for ras biomarker testing  Source text for Eikon:  Further company coverage:    (Gdynia Newsroom)",
        "date": "01072016",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Biocartis Group announces collaboration with Merck "
    },
    {
        "content": "Merck & Co Inc.'s drug to reverse the effects of muscle relaxants used during surgery has won U.S. approval.",
        "date": "12162015",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "FDA approves Merck drug to reverse effects of muscle relaxants "
    },
    {
        "content": "Dec 15 Merck & Co Inc.'s drug to reverse the effects of muscle relaxants used during surgery has won U.S. approval.",
        "date": "12152015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "FDA approves Merck drug to reverse effects of muscle relaxants "
    },
    {
        "content": "* Merck says acquisition to enhance position as semiconductor materials supplier",
        "date": "12142015",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Merck says acquires Ormet Circuits  no purchase price disclosed "
    },
    {
        "content": "Nov 12 Drugmaker Merck & Co Inc said the U.S. Court of Appeals for the Federal Circuit invalidated four patents related to the antibiotic  Cubicin  that expire in 2019 and 2020.",
        "date": "11122015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "U.S. appeals court invalidates four Merck Cubicin patents "
    },
    {
        "content": "Nov 13 The following bids  mergers  acquisitions and disposals were reported by 2100 GMT on Friday:",
        "date": "11132015",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Deals of the day-Mergers and acquisitions "
    },
    {
        "content": "NEW YORK  Nov 12 A former Bank of New York Mellon Corp employee was sentenced on Thursday to six months in prison after admitting to illegally making $737 000 trading on tips a friend at Merck & Co Inc supplied him about potential pharmaceutical mergers.",
        "date": "11122015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Ex-BNY Mellon employee sentenced to 6 months in U.S. prison "
    },
    {
        "content": "Merck & Co said an independent data monitoring committee recommended that the drugmaker continue a study of its experimental cholesterol drug  anacetrapib.",
        "date": "11132015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Panel recommends Merck & Co continue cholesterol drug study "
    },
    {
        "content": "FRANKFURT/LONDON A molecule that carries the recipe for making drugs inside body cells is exciting scientists and investors alike  attracting hundreds of millions of dollars in a scramble for the next promising area of biotechnology.",
        "date": "11122015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Germany  U.S. in hot pursuit of 'messenger' drug molecules "
    },
    {
        "content": "Drugmakers Merck & Co and Eli Lilly & Co are being investigated by the U.S. Attorney's Office in Pennsylvania and other federal agencies over drug pricing practices  the companies disclosed.",
        "date": "11072015",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "U.S. federal agencies investigate Merck  Lilly drug pricing "
    },
    {
        "content": "Nov 13 Merck & Co said an independent data monitoring committee recommended that the drugmaker continue a study of its experimental cholesterol drug  anacetrapib.",
        "date": "11132015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 1-Panel recommends Merck & Co continue cholesterol drug study "
    },
    {
        "content": "Nov 13 Merck & Co said an independent data monitoring committee recommended that the company continue a study of its experimental cholesterol drug  anacetrapib.",
        "date": "11132015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Panel recommends Merck continue cholesterol drug study "
    },
    {
        "content": "FRANKFURT/LONDON  Nov 12 A molecule that carries the recipe for making drugs inside body cells is exciting scientists and investors alike  attracting hundreds of millions of dollars in a scramble for the next promising area of biotechnology.",
        "date": "11122015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Germany  U.S. in hot pursuit of \"messenger\" drug molecules "
    },
    {
        "content": "CHICAGO  Nov 12 Merck & Co Inc's animal health unit will buy privately held Harrisvaccines Inc to expand its portfolio of animal vaccines as the U.S. livestock industry seeks new defenses against diseases  the companies said on Thursday.",
        "date": "11132015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck to buy Harrisvaccines to boost livestock vaccine portfolio "
    },
    {
        "content": "Merck & Co's drug to reverse the effects of muscle relaxants used in surgery is safe and effective enough to warrant approval  an independent panel to the U.S. Food and Drug Administration said.",
        "date": "11062015",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "FDA panel backs Merck & Co drug to reverse muscle relaxant effect "
    },
    {
        "content": "U.S. drugmakers Merck & Co and Eli Lilly & Co are being investigated by federal prosecutors over their drug-pricing practices  the companies disclosed.",
        "date": "11062015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "U.S. agencies investigate Merck  Lilly drug pricing "
    },
    {
        "content": "Nov 6 Merck & Co's drug to reverse the effects of muscle relaxants used in surgery is safe and effective enough to warrant approval  an independent panel to the U.S. Food and Drug Administration said.",
        "date": "11062015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 2-FDA panel backs Merck & Co drug to reverse muscle relaxant effect "
    },
    {
        "content": "Nov 6 U.S. drugmakers Merck & Co and Eli Lilly & Co are being investigated by federal prosecutors over their drug-pricing practices  the companies disclosed.",
        "date": "11062015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 1-U.S. agencies investigate Merck  Lilly drug pricing "
    },
    {
        "content": "Drugmakers Merck & Co and Eli Lilly & Co are being investigated by the U.S. Attorney's Office in Pennsylvania and other federal agencies over drug pricing practices  the companies disclosed.",
        "date": "11062015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "U.S. federal agencies investigate Merck  Lilly drug pricing "
    },
    {
        "content": "Nov 6 Drugmakers Merck & Co and Eli Lilly & Co are being investigated by the U.S. Attorney's Office in Pennsylvania and other federal agencies over drug pricing practices  the companies disclosed.",
        "date": "11062015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 1-U.S. federal agencies investigate Merck  Lilly drug pricing "
    },
    {
        "content": "Nov 6 Merck & Co is being investigated by the U.S. Attorney's Office in Pennsylvania over contracting and pricing of its asthma inhaler product  Dulera  the company said.",
        "date": "11062015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck & Co under Pennsylvania Attorney's Office probe over pricing "
    },
    {
        "content": "FRANKFURT  Oct 29 German drugmaker Bayer  saw underlying core earnings gain 28 percent in the third quarter  bolstered by sales of new drugs and the purchase of Merck & Co's consumer health business.",
        "date": "10292015",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Bayer adj EBITDA up 28 pct on new drugs "
    },
    {
        "content": "Merck & Co Inc  on Tuesday reported a higher-than-expected quarterly profit and raised its full-year forecast as demand for its diabetes and cancer drugs increased.",
        "date": "10272015",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck profit tops estimates on strong diabetes  cancer drug sales "
    },
    {
        "content": "Oct 27 Merck & Co Inc on Tuesday reported a higher-than-expected quarterly profit and raised its full-year forecast as demand for its diabetes and cancer drugs increased.",
        "date": "10272015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 3-Merck profit tops estimates on strong diabetes  cancer drug sales "
    },
    {
        "content": "Oct 26 Merck & Co's approved Keytruda lung cancer treatment provided superior overall survival to chemotherapy in a late-stage study of patients with advanced disease whose tumors produce a protein called PD-L1 associated with increased risk of the disease.",
        "date": "10262015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck's Keytruda extends survival in lung cancer study "
    },
    {
        "content": "* Says januvia sales got a $100 million boost in third quarter from timing of customer buying",
        "date": "10272015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck says expects januvia to retain strong position as add-on diabetes therapy despite favorable data seen with lilly's rival jardiance "
    },
    {
        "content": "Oct 27 Drugmaker Merck & Co Inc reported a near 5 percent drop in quarterly revenue as a strong dollar offset strong demand for its diabetes drugs.",
        "date": "10272015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck revenue down 5 pct  hurt by strong dollar "
    },
    {
        "content": "LOS ANGELES  Oct 21 Investor concerns over accounting practices at Valeant Pharmaceuticals International Inc have put a spotlight on the little-known and fast-growing specialty pharmacy industry.",
        "date": "10222015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Specialty pharmacies in spotlight as Valeant ties questioned "
    },
    {
        "content": "FRANKFURT  Oct 20 Merck has cleared a major anti-trust hurdle to its planned $17 billion acquisition of Sigma-Aldrich with the latter's agreed sale of assets to Honeywell  the German drugmaker said on Tuesday.",
        "date": "10202015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck clears major hurdle to Sigma-Aldrich takeover "
    },
    {
        "content": "* Achieves first milestone in immuno-oncology collaboration with Merck & Co.  Inc.",
        "date": "10152015",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Ablynx gets first milestone in immuno-oncology deal with Merck & Co. "
    },
    {
        "content": "NEW YORK  Oct 13 A former Merck & Co Inc  employee was sentenced to more than three years in prison on Tuesday for engaging in an insider trading scheme by tipping a friend at Bank of New York Mellon Corp about potential pharmaceutical mergers.",
        "date": "10142015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Ex-Merck employees gets 3 years in prison for insider trading "
    },
    {
        "content": "* Only a handful of Indian firms making biosimilars for US  EU",
        "date": "10142015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "India risks missing boat as biosimilars shake up drug industry "
    },
    {
        "content": "(Corrects to add RIC in first bullet) Bionomics Ltd :  * Merck investment and pain partnership extended    * Merck &co.  inc. to make US$9 million investment in Bionomics  * Says extended its strategic collaboration with Merck & co.  inc.  Kenilworth NJ  * Says separately  Merck & co.  will also purchase 21.7 million ordinary shares at A$0.5938  a 29% premium to bionomics' closing price on 7 October 2015  * Says collaboration the discovery and development of drug candidates for the treatment of ",
        "date": "10082015",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "REFILE-BRIEF-Bionomics announces extension of strategic collaboration with Merck & Co.  Inc "
    },
    {
        "content": "FRANKFURT  Oct 14 Germany's Merck KGaA  said it would scrap its divisional brands Merck Serono and Merck Millipore and do business simply as Merck outside North America.",
        "date": "10142015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Germany's Merck KGaA scraps unit brands "
    },
    {
        "content": "NEW YORK A former Merck & Co Inc employee was sentenced to more than three years in prison on Tuesday for engaging in an insider trading scheme by tipping a friend at Bank of New York Mellon Corp about potential pharmaceutical mergers.",
        "date": "10142015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Ex-Merck employees gets three years in prison for insider trading "
    },
    {
        "content": "The U.S. Food and Drug Administration on Friday approved Merck & Co Inc's immunotherapy  Keytruda  for patients with the most common form of lung cancer whose tumors produce a specific biological marker.",
        "date": "10022015",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "FDA expands approval of Merck's Keytruda to lung cancer "
    },
    {
        "content": "* Says it started investigating a novel  potential first-in- class bi-functional immunotherapy in clinical trials",
        "date": "10012015",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Corrected-Merck KGaA says avelumab alliance with Pfizer on track "
    },
    {
        "content": "Oct 2 The U.S. Food and Drug Administration on Friday approved Merck & Co Inc's immunotherapy  Keytruda  for patients with the most common form of lung cancer whose tumors produce a specific biological marker.",
        "date": "10022015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 3-U.S. FDA expands approval of Merck's Keytruda to lung cancer "
    },
    {
        "content": "Oct 2 The U.S. Food and Drug Administration granted accelerated approval for Merck & Co's  immunotherapy  Keytruda  in patients with a form of lung cancer.",
        "date": "10022015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "FDA approves Merck's Keytruda for use in lung cancer "
    },
    {
        "content": "Sept 28 Merck & CO said its Type 2 diabetes drug had been approved in Japan  marking the first approval for the once-weekly drug.",
        "date": "09282015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck's once-weekly diabetes drug approved in Japan "
    },
    {
        "content": "(Adds futures prices  company news items)     LONDON  Sept 25 European equity futures rose on Friday  although the region's major indexes could still end the week with a loss following blows dealt to the market this week by an emissions test debacle at Volkswagen and new signs of a slowdown in China.     The prospect of a U.S interest rate rise has also weighed on equities  and Federal Reserve head Janet Yellen said late on Thursday she expects the U.S. central bank to begin raisi",
        "date": "09252015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "European Factors to Watch-Futures rise but markets could still have weekly loss "
    },
    {
        "content": "* Says is progressing toward completion of Sigma - Aldrich acquisition",
        "date": "09282015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Merck KGaA says closing of Sigma-Aldrich takeover expected soon "
    },
    {
        "content": "FRANKFURT  Sept 25 The DAX top-30 index  looked set to open 1.7 percent higher on Friday  according to premarket data from brokerage Lang & Schwarz at 0605 GMT.",
        "date": "09252015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "German stocks - Factors to watch on September 25 "
    },
    {
        "content": "(Adds company news items)     LONDON  Sept 25 European stocks were seen opening higher on Friday  although the region's major indexes could still end the week with a loss following blows dealt to the market this week by an emissions test debacle at Volkswagen and new signs of a slowdown in China.     The prospect of a U.S interest rate rise has also weighed on equity markets  and Federal Reserve head Janet Yellen said late on Thursday that she expects the U.S. central bank to begi",
        "date": "09252015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "European Factors to Watch-Shares seen opening higher "
    },
    {
        "content": "Merck & Co said its experimental once-weekly diabetes drug was found to be as good as its blockbuster Januvia  which is taken once a day.",
        "date": "09162015",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck's once-weekly diabetes drug found effective in study "
    },
    {
        "content": "Sept 17 Eli Lilly and Co's new Jardiance pill slashed deaths by 32 percent in patients with type 2 diabetes at risk of heart attack and stroke  a finding that could make it a mainstay diabetes treatment and triple its use  according to researchers and analysts.",
        "date": "09172015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 3-Lilly diabetes drug slashes deaths in patients with heart risk "
    },
    {
        "content": "Sept 17 Advaxis Inc said its experimental cancer vaccine was found more effective in improving survival rates of cervical cancer patients than standard therapy  validating the technology behind its pipeline of cancer treatments.",
        "date": "09172015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Advaxis therapy improves survival rates in cervical cancer patients "
    },
    {
        "content": "A Delaware federal judge has disqualified an expert retained by New Jersey-based drugmaker Merck & Co in patent litigation against two generic rivals because the expert previously helped defend Apotex Inc against Merck's lawsuit over the same drug.",
        "date": "09082015",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Judge nixes Apotex's former expert in new role for Merck "
    },
    {
        "content": "LONDON  Sept 7 Britain's healthcare cost-effectiveness watchdog NICE on Monday recommended use of Merck's immunotherapy drug Keytruda  after the U.S. drugmaker promised to supply it to the state health service at a discounted price.",
        "date": "09072015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UK backs use of Merck cancer immunotherapy after price discount "
    },
    {
        "content": "Aug 28 A class of diabetes drugs that include Merck & Co Inc's Januvia have been linked with severe joint pain  the U.S. Food and Drug Administration said on Friday.",
        "date": "08282015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "FDA warns of severe joint pain risk with DPP-4 diabetes drugs "
    },
    {
        "content": "FRANKFURT/BERLIN  Aug 24 The DAX top-30 index  looked set to open 3.6 percent lower on Monday  according to premarket data from brokerage Lang & Schwarz at 0603 GMT.",
        "date": "08242015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "German stocks - Factors to watch on August 24 "
    },
    {
        "content": "Aug 28 A class of diabetes drugs that include Merck & Co Inc's Januvia has been linked with severe joint pain  the U.S. Food and Drug Administration said on Friday.",
        "date": "08282015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 1-FDA warns of severe joint pain risk with DPP-4 diabetes drugs "
    },
    {
        "content": "Merck & Co Inc  reported a better-than-expected quarterly profit and boosted its full-year earnings forecast as demand for its diabetes and cancer drugs increased.",
        "date": "07282015",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck raises forecast on strong sales of diabetes  cancer drugs "
    },
    {
        "content": "BRUSSELS  July 22 Belgian biotech group Ablynx  on Wednesday said it had tripled its research deal with U.S. drugmaker Merck & Co leading to potential milestone payments of about 4 billion euros ($4.38 billion).",
        "date": "07222015",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Belgium's Ablynx triples cooperation deal with Merck & Co "
    },
    {
        "content": "July 28 Merck & Co Inc reported a better-than-expected quarterly profit and boosted its full-year earnings forecast as demand for its diabetes and cancer drugs increased.",
        "date": "07282015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 1-Merck raises forecast on strong sales of diabetes  cancer drugs "
    },
    {
        "content": "July 28 Merck & Co Inc reported a nearly 11 percent drop in quarterly revenue as a strong dollar and the sale of its consumer care business overshadowed strong demand for its diabetes drugs.",
        "date": "07282015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Strong dollar weighs on Merck revenue "
    },
    {
        "content": "* Significantly expands its immuno-oncology collaboration with Merck & Co Inc",
        "date": "07222015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "BRIEF-Ablynx expands its immuno-oncology collaboration with Merck & Co "
    },
    {
        "content": "* Merck is market leader in liquid crystals   (Adds details on competitors  investment)",
        "date": "06192015",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "UPDATE 1-Merck aims to be leader in OLED materials by 2018 "
    },
    {
        "content": "DARMSTADT  Germany  June 19 Germany's Merck  aims to be a leading maker of OLED (organic light-emitting diode) materials by 2018  its head of chemicals said on Friday.",
        "date": "06192015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck aims to be leader in OLED materials by 2018 "
    },
    {
        "content": "June 16 Merck Manuals  the widely used health guides provided by drugmaker Merck & Co  are moving to a digital-only format in 10 different languages as part of an effort to educate the global community on medical issues.",
        "date": "06162015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck Manuals health guides go digital  and free  in global push "
    },
    {
        "content": "NEW YORK Merck & Co Inc has agreed to pay $5.9 million to resolve claims that a former unit fraudulently promoted a drug used to treat pink eye for unapproved purposes  U.S. authorities announced on Wednesday.",
        "date": "06172015",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck to pay $5.9 million for misleading marketing of pink eye drug: U.S "
    },
    {
        "content": "NEW YORK  June 17 A unit of Merck & Co Inc  has agreed to pay $5.9 million to resolve claims that it fraudulently promoted a drug used to treat pink eye for unapproved purposes  U.S. authorities announced on Wednesday.",
        "date": "06172015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck to pay $5.9 mln for misleading marketing of pink eye drug: U.S. "
    },
    {
        "content": "June 15 The following bids  mergers  acquisitions and disposals were reported by 2000 GMT on Monday:",
        "date": "06152015",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Deals of the day- Mergers and acquisitions "
    },
    {
        "content": "NEW YORK  June 17 Merck & Co Inc has agreed to pay $5.9 million to resolve claims that a former unit fraudulently promoted a drug used to treat pink eye for unapproved purposes  U.S. authorities announced on Wednesday.",
        "date": "06172015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 1-Merck to pay $5.9 mln for misleading marketing of pink eye drug: U.S. "
    },
    {
        "content": "NEW YORK  June 17 Merck & Co Inc has agreed to pay $5.9 million to resolve claims that a former unit fraudulently promoted a drug used to treat pink eye for unapproved purposes  U.S. authorities announced on Wednesday.",
        "date": "06172015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "CORRECTED-Merck to pay $5.9 mln for misleading marketing of pink eye drug: U.S. "
    },
    {
        "content": "BRUSSELS The European Commission said on Monday it had approved German drugmaker Merck's $17 billion acquisition of Sigma-Aldrich Corp following the U.S. company's pledges to sell assets in Germany.",
        "date": "06152015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "European Commission approves Merck's $17 billion Sigma-Aldrich buy "
    },
    {
        "content": "* Signs an agreement with Merck Sharp & Dohme SA (MSD)  to market Orvatez in Spain",
        "date": "06122015",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "BRIEF-Rovi signs deal with Merck to market Orvatez in Spain "
    },
    {
        "content": "BRUSSELS  June 15 The European Commission said on Monday it had approved German drugmaker Merck's $17 billion acquisition of Sigma-Aldrich Corp following the U.S. company's pledges to sell assets in Germany.",
        "date": "06152015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "European Commission approves Merck's $17 bln Sigma-Aldrich buy "
    },
    {
        "content": "Two former Merck & Co Inc scientists accusing the drugmaker of falsifying tests of its exclusive mumps vaccine said in a court filing on Monday that Merck is refusing to respond to questions about the efficacy of the vaccine.",
        "date": "06042015",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck accused of stonewalling in mumps vaccine antitrust lawsuit "
    },
    {
        "content": "A Merck & Co drug that helps the immune system fight cancer was about twice as effective as the current standard therapy for patients with recurrent or advanced head and neck cancers  according to study data released on Friday.",
        "date": "05312015",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck immunotherapy appears effective in head and neck cancer: study "
    },
    {
        "content": "A Merck & Co drug that helps the immune system fight cancer was about twice as effective as the current standard therapy for patients with recurrent or advanced head and neck cancers  according to study data released on Friday.",
        "date": "05292015",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck immunotherapy appears effective in head and neck cancer-study "
    },
    {
        "content": "May 29 A Merck & Co drug that helps the immune system fight cancer was about twice as effective as the current standard therapy for patients with recurrent or advanced head and neck cancers  according to study data released on Friday.",
        "date": "05292015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 1-Merck immunotherapy appears effective in head and neck cancer-study "
    },
    {
        "content": "Thomson Reuters May 25  2015 - Corporate Meetings for US companies for Week ahead.         S&P 500 Earnings - MONTH AHEAD     Dividends                            Non S&P 500 - Weekly             Federal Reserve events               ConferenceCall/Webcast - Weekly  Meetings - Weekly                                Xtra users can see more details on conference calls & webcasts by hovering your mouse  over the RIC  right click  no click on Related Co Data  now click on Co Events.             ** For",
        "date": "05262015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "DIARY-U.S. MEETINGS/WEEK AHEAD "
    },
    {
        "content": "New data to be released this weekend should help deepen the understanding of how broadly new drugs that unleash the body's immune system to fight cancer can be used.",
        "date": "05282015",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "New drugs from Bristol  Merck at forefront of cancer meeting "
    },
    {
        "content": "BRUSSELS  May 27 German drugmaker Merck  has offered concessions in a bid to convince European Union antitrust regulators to clear its proposed $17 billion acquisition of U.S. peer Sigma-Aldrich Corp.",
        "date": "05272015",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck offers EU concessions over $17 bln Sigma-Aldrich buy "
    },
    {
        "content": "May 22 European regulators have recommended approval of Merck & Co Inc's immune system-boosting cancer drug Keytruda  following a similar green light last month for Bristol-Myers Squibb Co's rival product Opdivo.",
        "date": "05222015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck follows Bristol with EU green light for immune cancer drug "
    },
    {
        "content": "NEW YORK Brazil's JBS SA  the world's largest meatpacker  this year will look at opportunities for acquisitions in North and South America and Australia  Chief Executive Wesley Batista said on Wednesday.",
        "date": "05212015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Brazil's JBS looking for deals in Americas  Australia: CEO "
    },
    {
        "content": "A class action accusing Merck & Co Inc of concealing from investors the risks of its now-withdrawn painkiller Vioxx may go forward  a federal judge has ruled.",
        "date": "05142015",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck loses bid to escape investor lawsuit over Vioxx "
    },
    {
        "content": "MUMBAI India's Supreme Court has barred Glenmark Pharmaceuticals from making and selling copies of U.S. drugmaker Merck's diabetes drugs Januvia and Janumet  according to a court document released on Friday.",
        "date": "05152015",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Indian court bars Glenmark from selling Merck drug copies "
    },
    {
        "content": "Thomson Reuters May 15  2015 - Corporate Meetings for US companies for Week ahead.         S&P 500 Earnings - MONTH AHEAD     Dividends                            Non S&P 500 - Weekly             Federal Reserve events               ConferenceCall/Webcast - Weekly  Meetings - Weekly                                Xtra users can see more details on conference calls & webcasts by hovering your mouse  over the RIC  right click  no click on Related Co Data  now click on Co Events.             ** For",
        "date": "05152015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "DIARY-U.S. MEETINGS/WEEK AHEAD "
    },
    {
        "content": "MUMBAI  May 15 India's Supreme Court has barred Glenmark Pharmaceuticals from making and selling copies of U.S. drugmaker Merck's diabetes drugs Januvia and Janumet  according to a court document released on Friday.",
        "date": "05152015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 1-Indian court bars Glenmark from selling Merck drug copies "
    },
    {
        "content": "MUMBAI  May 15 India's Supreme Court has blocked Glenmark Pharmaceuticals Ltd from selling copies of U.S. drugmaker Merck & Co Inc's diabetes drugs Januvia and Janumet  sources with knowledge of the matter said after a court hearing on Friday.",
        "date": "05152015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "India's Supreme Court bars Glenmark from selling copies of Merck diabetes drugs-sources "
    },
    {
        "content": "April 28 Investors betting that Bristol-Myers Squibb will emerge as the leading player in a hot new class of cancer drugs hit the pause button on Tuesday as a rival therapy from Merck & Co showed much higher sales.",
        "date": "04292015",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "RPT-Strong Merck cancer drug sales upstage rival Bristol-Myers "
    },
    {
        "content": "April 24 Merck and Co Inc presented trial results on Friday showing that a once-daily combination of two experimental pills cured 95 percent of previously untreated hepatitis C patients after 12 weeks.",
        "date": "04242015",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck oral hepatitis C regimen shows 95 pct cure rate "
    },
    {
        "content": "April 27 Merck and Co's diabetes drug Januvia achieved the main goal of a long-awaited heart safety study  according to preliminary results released by the drugmaker on Monday  likely removing a cloud of uncertainty from its biggest product.",
        "date": "04272015",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "UPDATE 2-Merck diabetes drug Januvia meets heart safety target "
    },
    {
        "content": "April 27 Merck and Co's diabetes drug Januvia achieved the main goal of a long-awaited heart safety study  according to preliminary results released by the company on Monday  likely removing a cloud of uncertainty from its biggest product.",
        "date": "04272015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck's diabetes drug Januvia succeeds in heart safety trial "
    },
    {
        "content": "Investors betting that Bristol-Myers Squibb will emerge as the leading player in a hot new class of cancer drugs hit the pause button on Tuesday as a rival therapy from Merck & Co showed much higher sales.",
        "date": "04282015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Strong Merck cancer drug sales upstage rival Bristol-Myers "
    },
    {
        "content": "NEW YORK  April 28 Two of three major U.S. stock indexes rose modestly on Tuesday as Merck posted strong earnings and IBM raised its dividend  while European stocks slid on weak corporate results and oil prices were flat to lower on expectations that U.S. crude stockpiles have reached record highs.",
        "date": "04282015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "GLOBAL MARKETS-U.S. shares rebound; oil pares gains after Iran ship seizure "
    },
    {
        "content": "The Dow and S&P 500 ended a volatile session higher on Tuesday  helped by strong earnings from Merck and gains in IBM after it boosted its dividend  while the Nasdaq fell with Apple.",
        "date": "04282015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Dow  S&P 500 end up with Merck  IBM; Nasdaq slips with Apple "
    },
    {
        "content": "* Dow up 0.4 pct  S&P up 0.28 pct  Nasdaq down 0.1 pct   (Updates to close)",
        "date": "04282015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "US STOCKS-Dow  S&P 500 end up with Merck  IBM; Nasdaq slips with Apple "
    },
    {
        "content": "* Dow up 0.3 pct  S&P up 0.2 pct  Nasdaq down 0.04 pct   (Updates to late afternoon)",
        "date": "04282015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "US STOCKS-Wall St edges up with Merck  IBM; Nasdaq slips with Apple "
    },
    {
        "content": "NEW YORK  April 28 U.S. shares rebounded in afternoon trading on Tuesday  boosted by strong earnings from Merck and a dividend hike by IBM  while oil prices pared gains on expectations that U.S. crude stockpiles have reached record highs.",
        "date": "04282015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "GLOBAL MARKETS-U.S. shares edge higher; oil pares gains after Iran ship seizure "
    },
    {
        "content": "Merck & Co Inc's Keytruda  approved for treating melanoma  was shown in a trial to shrink tumors in nearly half of advanced lung cancer patients with high levels of a protein used by tumors to evade the body's own disease-fighting cells.",
        "date": "04192015",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck's Keytruda shrinks lung cancer tumors  FDA approval sought "
    },
    {
        "content": "FRANKFURT Germany's Merck  aims to quickly repay the up to $5 billion in bank loans it needed to fund the $17 billion acquisition of U.S. lab supplies company Sigma-Aldrich   its finance chief told daily Boersen-Zeitung.",
        "date": "04182015",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck aims to quickly repay up to $5 billion in loans: CFO in Boersen-Zeitung "
    },
    {
        "content": "* Indexes up: Dow 0.4 pct  S&P 0.3 pct  Nasdaq 0.2 pct   (Updates to early afternoon  changes comment)",
        "date": "04282015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "US STOCKS-Wall St moves higher after erratic early trading "
    },
    {
        "content": "Merck & Co's  shares jumped almost 5 percent after the U.S. drugmaker reported better-than-expected quarterly results and released favorable data late Monday about the safety of its Januvia diabetes drug. |\u00a0Video ",
        "date": "04282015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck shares jump on strong earnings  Januvia safety data "
    },
    {
        "content": "April 19 Merck & Co Inc's Keytruda  approved for treating melanoma  was shown in a trial to shrink tumors in nearly half of advanced lung cancer patients with high levels of a protein used by tumors to evade the body's own disease-fighting cells.",
        "date": "04192015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "CORRECTED-Merck's Keytruda shrinks lung cancer tumors  FDA approval sought "
    },
    {
        "content": "April 19 Merck & Co Inc said on Sunday it has submitted an application to the U.S. Food and Drug Administration for its drug Keytruda as a treatment for advanced non-small cell lung cancer  the most common form of the disease.",
        "date": "04192015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck files for FDA approval of Keytruda in lung cancer "
    },
    {
        "content": "FRANKFURT  April 18 Germany's Merck  aims to quickly repay the up to $5 billion in bank loans it needed to fund the $17 billion acquisition of U.S. lab supplies company Sigma-Aldrich  its finance chief told daily Boersen-Zeitung.",
        "date": "04182015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck aims to quickly repay up to $5 bln in loans -CFO in Boersen-Zeitung "
    },
    {
        "content": "* Indexes up: Dow 0.3 pct  S&P 0.2 pct  Nasdaq 0.2 pct   (Adds details  comment  updates prices)",
        "date": "04282015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "US STOCKS-Wall St reverses course to trade higher "
    },
    {
        "content": "(The following statement was released by the rating agency) CHICAGO  April 13 (Fitch) Fitch Ratings has downgraded Merck & Co.'s (Merck)  long-term Issuer Default Rating (IDR) by one notch to 'A' and revised the Rating  Outlook to Stable from Negative. In addition  the company's short-term IDR has  been affirmed at 'F1'. Merck had $21.7 billion in outstanding debt at Dec. 31  2014. A full list of  Fitch's ratings actions follows at the end of this release.  KEY RATING DRIVERS --Fitch expects MRK",
        "date": "04132015",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Fitch Downgrades Merck's L-T IDR to 'A'; Outlook Revised to Stable "
    },
    {
        "content": "FRANKFURT  March 20 Germany's Merck KGaA  will promote its deputy chief executive  Stefan Oschmann  to the top job next year to replace Karl-Ludwig Kley  Manager Magazin reported on Friday  citing company sources.",
        "date": "03202015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck KGaA's deputy chief Oschmann set to become CEO - Manager Magazin "
    },
    {
        "content": "LONDON  March 11 Merck & Co's cancer drug Keytruda  which works by boosting the immune system but has yet to be licensed in Europe  is the first medicine to be made available to patients in Britain under a new early access scheme.",
        "date": "03112015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck cancer drug is first approved under UK early access scheme "
    },
    {
        "content": "March 13 Merck & Co Inc said it expected to be denied U.S. approval for its sugammadex injection  after the U.S. Food and Drug Administration said it would conduct additional site inspections related to a study of the drug.",
        "date": "03132015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck expects to be denied approval for sugammadex injection again "
    },
    {
        "content": "March 13 Merck & Co Inc said it expects its long-delayed drug to reverse the effects of anesthesia to be denied U.S. approval after U.S. regulators said they need to conduct more site inspections related to a study of the drug.",
        "date": "03132015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 1-Merck expects to be denied approval for sugammadex injection again "
    },
    {
        "content": "LONDON/GENEVA Final stage trials of an Ebola vaccine being developed by Merck and NewLink Genetics will begin in Guinea on March 7  the World Health Organization said on Thursday.",
        "date": "03052015",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Guinea to start final trials of Ebola vaccines this week "
    },
    {
        "content": "* WHO says effective Ebola shot could be a \"game-changer\"   (Adds details of \"ring vaccination\" plans  quotes)",
        "date": "03052015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 2-Guinea to start final trials of Ebola vaccines this week "
    },
    {
        "content": "GENEVA  March 5 Merck & Co and NewLink Genetics Corp's Ebola vaccine will begin a Phase III trial in Guinea on March 7  the final stage of testing  the World Health Organization said on Thursday.",
        "date": "03052015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck-NewLink Ebola vaccine Phase III trial to start March 7 "
    },
    {
        "content": "* Biosimilars expected to disrupt market for biotech medicines   (Adds detail on price discount  paragraph 7)",
        "date": "02252015",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "UPDATE 1-Biosimilar copies of blockbuster drug launch in major EU markets "
    },
    {
        "content": "* Biosimilars expected to disrupt market for biotech medicines",
        "date": "02252015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Biosimilar copies of blockbuster drug launch in major EU markets "
    },
    {
        "content": "NEW YORK  Feb 19 A former Merck & Co Inc  finance analyst pleaded guilty on Thursday to participating in an insider trading scheme in which he passed tips about potential pharmaceutical mergers to a friend who worked at Bank of New York Mellon Corp.",
        "date": "02192015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Ex-Merck analyst pleads guilty to U.S. insider trading charges "
    },
    {
        "content": "* Indexes: Dow up 0.04 pct  S&P down 0.4 pct  Nasdaq down 0.2 pct   (Updates to close)",
        "date": "02042015",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "US STOCKS-Wall St ends lower with oil prices  renewed Greece worries "
    },
    {
        "content": "Merck & Co on Wednesday said U.S. regulators intend to rescind the \"breakthrough therapy\" designation for its  combination treatment for hepatitis C because other new drugs are available  a decision that could delay approval of the Merck product by several months.",
        "date": "02042015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck says hepatitis C treatment to lose \"breakthrough\" status "
    },
    {
        "content": "Feb 2 At least 40 major U.S. companies have substantial exposure to Venezuela's deepening economic crisis  and could collectively be forced to take billions of dollars of write downs  a Reuters analysis shows.",
        "date": "02022015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "RPT-INSIGHT-US companies face billions in Venezuela currency losses  Reuters analysis shows "
    },
    {
        "content": "* Indexes: Dow up 0.1 pct  S&P off 0.3 pct  Nasdaq down 0.1 pct   (Updates to afternoon)",
        "date": "02042015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "US STOCKS-S&P  Nasdaq slip after 2-day run up; energy drops with oil "
    },
    {
        "content": "Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the \"breakthrough therapy\" designation for its  combination treatment for hepatitis C because other new drugs are available  a decision that could delay approval of the Merck product by several months.",
        "date": "02042015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 3-Merck says hepatitis C treatment to lose \"breakthrough\" status "
    },
    {
        "content": "Feb 2 At least 40 major U.S. companies have substantial exposure to Venezuela's deepening economic crisis  and could collectively be forced to take billions of dollars of write downs  a Reuters analysis shows.",
        "date": "02022015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "INSIGHT-US companies face billions in Venezuela currency losses  Reuters analysis shows "
    },
    {
        "content": "* Indexes: Dow up 0.1 pct  S&P off 0.4 pct  Nasdaq down 0.2 pct   (Updates to midday  changes byline)",
        "date": "02042015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "US STOCKS-S&P  Nasdaq down after 2-day run up; biotechs  energy fall "
    },
    {
        "content": "* Indexes: Dow up 0.16 pct  S&P off 0.22 pct  Nasdaq 0.31 pct   (Adds ISM services data)",
        "date": "02042015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "US STOCKS-Wall St dips after 2-day run as energy rally stalls "
    },
    {
        "content": "* Indexes off: Dow 0.2 pct  S&P 0.47 pct  Nasdaq 0.59 pct   (Updates to market open)",
        "date": "02042015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "US STOCKS-Wall St down after 2-day run after ADP as energy drags "
    },
    {
        "content": "* Futures off: Dow 18 pts  S&P 6.25 pts  Nasdaq 14.5 pts   (Adds ADP data  quote)",
        "date": "02042015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "US STOCKS-Wall St to open lower after 2-day run  ADP data "
    },
    {
        "content": "Feb 4 Merck & Co on Wednesday reported slightly disappointing fourth quarter sales and predicted 2015 earnings below analyst forecasts  citing the negative impact of the stronger dollar  as most of its U.S. rivals have done in making their own cautious forecasts.",
        "date": "02042015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck issues cautious 2015 forecast  citing dollar "
    },
    {
        "content": "LONDON  Jan 23 Europe recommended seven new drugs for approval on Friday  including two antibiotics for skin infections and a new treatment option for HIV.",
        "date": "01232015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Europe recommends seven new medicines for approval "
    },
    {
        "content": "Jan 20 Johnson & Johnson surprised investors by detailing the degree to which a strong dollar will hurt sales abroad this year  and industry watchers say Wall Street is underestimating the likely hit to other U.S.-based rivals such as Pfizer Inc and Merck & Co.",
        "date": "01202015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Johnson & Johnson's forex warning a sign for rival drugmakers "
    },
    {
        "content": "CHICAGO Merck & Co Inc is funding the testing of lower dosages of its controversial cattle growth drug Zilmax  in a move that livestock experts say is crucial if the company is to resume sales of the product to the U.S. beef industry.",
        "date": "01192015",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Exclusive: Merck funds tests of lower Zilmax doses as seen seeking way to resume sales "
    },
    {
        "content": "Jan 13 Eli Lilly & Co signed two separate deals with Merck & Co Inc and Bristol-Myers Squibb Co to test combinations of its cancer treatments with two recently approved therapies that belong to a promising new class of drugs.",
        "date": "01132015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Lilly to test combinations with Merck  Bristol-Myers' cancer drugs "
    },
    {
        "content": "Jan 12 Bristol-Myers Squibb and Merck & Co broke further away from rival drugmakers in the race to treat lung cancer with a new generation of immune system therapies  adding pressure on the likes of Roche and AstraZeneca to play catch-up.",
        "date": "01122015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck  Bristol heat up immunotherapy race in lung cancer "
    },
    {
        "content": "Merck & Co said it would fast track its plans to submit new drugs for hepatitis C and lung cancer for regulatory approval.",
        "date": "01122015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck speeds up drug-submission plans for Hep C  lung cancer "
    },
    {
        "content": "Jan 12 Merck & Co said it would fast track its plans to submit new drugs for hepatitis C and lung cancer for regulatory approval.",
        "date": "01122015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 1-Merck speeds up drug-submission plans for Hep C  lung cancer "
    },
    {
        "content": "Jan 12 Merck & Co has put on fast track its plans to submit new drugs for hepatitis C and lung cancer for regulatory approval  in an attempt to close the gap with competitors in two lucrative segments  the Wall Street Journal reported.",
        "date": "01122015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck speeds up drug-submission plans for Hep C  lung cancer -WSJ "
    },
    {
        "content": "GENEVA The clinical trial of an Ebola vaccine developed by Merck and NewLink resumed on Monday at a lower dose after a pause to assess complaints of joint pains in some volunteers  the University of Geneva hospital said.",
        "date": "01052015",
        "name": "Merck & Company Inc",
        "news_type": "topStory",
        "symbol": "MRK",
        "title": "Merck-NewLink Ebola vaccine trial resumes at lower dose: Geneva hospital "
    },
    {
        "content": "Jan 5 Cempra Inc moved a step closer to approval for its lead antibiotic  solithromycin  after an oral version of the potential blockbuster met the main goal in a late-stage trial.",
        "date": "01052015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "UPDATE 2-Cempra's lead oral antibiotic meets main goal in late-stage trial "
    },
    {
        "content": "GENEVA  Jan 5 The clinical trial of an Ebola vaccine developed by Merck and NewLink resumed on Monday at a lower dose after a pause to assess complaints of joint pains in some volunteers  the University of Geneva hospital said.",
        "date": "01052015",
        "name": "Merck & Company Inc",
        "news_type": "normal",
        "symbol": "MRK",
        "title": "Merck-NewLink Ebola vaccine trial resumes at lower dose -Geneva hospital "
    }
]